[
  {
    "objectID": "About_Me.html",
    "href": "About_Me.html",
    "title": "About Me",
    "section": "",
    "text": "Hello! My name is Naomi Yamaguchi, and I am currently a first-year graduate student in the Data Science and Analytics (DSAN) Master’s program at Georgetown University.\n\n\n\nThis is me\n\n\nI grew up in Maryland and studied undergraduate at Salisbury University where I majored with a B.S in Statistics and minored with Data Science. During my undergraduate, I was selected to be part of research project with computer science department and gained real world skills from several internships. After graduation, I spent my summer as a revenue management analyst intern at Georgetown before returning to school to join the world of data science.\nOutside of school and work, my hobbies include adventure, workout, playing with my dogs, window shopping, attending concert/festival, and exploring the DC with my friends. Thanks for checking out my portfolio!\n GU netID: ny159 \n LinkedIn: Click here for my LinkedIn"
  },
  {
    "objectID": "Decision_Tree.html#regression",
    "href": "Decision_Tree.html#regression",
    "title": "Decision Trees",
    "section": "Regression",
    "text": "Regression"
  },
  {
    "objectID": "Introduction.html",
    "href": "Introduction.html",
    "title": "Introduction",
    "section": "",
    "text": "Why do we always hear people compare the United States and other countries health care system? Health insurance in the United States is always a problem governments and communities face. Compared to other countries, the U.S. does not have the flexibility and accessibility of the health care system for all citizens. Many Americans are paying out-of-pocket to access into medical system and some have no access. President Obama took this community challenge seriously and passed two laws to make a change in the healthcare system.\nThe Affordable Care Act (ACA) is the name for the comprehensive health care reform law and its amendments which addresses health insurance coverage, health care costs, and preventive care, also known as Obama care. Two laws significantly affect American health insurance: The Patient Protection and Affordable Care Act. Both laws are passed by President Barack Obama on March 23, 2010, and were amended by the Health Care and Education Reconciliation Act on March 30, 2010.\n\n\n\nACA\n\n\nThe ACA didn’t achieve its intended results as effectively as anticipated. As outlined by the American Action Forum, the ACA led to a direct hike in expenses for drug producers by introducing a new tax tied to the revenue from a company’s branded drug sales. While the overall prescription drug prices saw a reduction, the prices of branded prescription drugs experienced a rise. Between 2011 and 2015, this specific tax cost the pharmaceutical sector $14.1 billion. Additionally, the ACA extended Medicaid coverage to approximately 13 million Americans, mandated health insurance, and introduced new taxes on higher-income households to finance healthcare expenses, subsequently raising yearly premiums and out-of-pocket costs for numerous households."
  },
  {
    "objectID": "Introduction.html#aca-health-insurance-coverage-change",
    "href": "Introduction.html#aca-health-insurance-coverage-change",
    "title": "Introduction",
    "section": "",
    "text": "Health insurance in the United States is always a problem governments and communities face. Compared to other countries, the U.S. does not have the flexibility and accessibility of the health care system for all citizens. President Obama took this community challenge seriously and passed two laws to make a change in the healthcare system.\nThe Affordable Care Act (ACA) is the name for the comprehensive health care reform law and its amendments which addresses health insurance coverage, health care costs, and preventive care, also known as Obama care. Two laws significantly affect American health insurance: The Patient Protection and Affordable Care Act. Both laws are passed by President Barack Obama on March 23, 2010, and were amended by the Health Care and Education Reconciliation Act on March 30, 2010.\n\n\n\nACA\n\n\nIn this project, I used data gathering, data cleaning, clustering, dimensionality reduction, decision trees include classification and regression, and ARM to focus background of Obama care and Medicaid health insurance changes.\nYou MUST find TWO academic publications, relevant to your topic, and summarize (and cite) them in your introduction tab.\nThis section should include paragraphs that summarize the topic, why it is important, why the reader should continue, what work has been done in the past by other research groups, what are the “different points of views”/interpretations in the literature, what are you exploring, what questions are you trying to address, what are your goals and hypothesis, etc"
  },
  {
    "objectID": "Introduction.html#research-the-articles-related-to-aca-here",
    "href": "Introduction.html#research-the-articles-related-to-aca-here",
    "title": "Introduction",
    "section": "Research the articles related to ACA here",
    "text": "Research the articles related to ACA here\nTo explore the effect and impact by ACA across the nation, the following questions will be answered in this research. Each question will be addressed and answered with the backing of data throughout the project and in the conclusion with examples."
  },
  {
    "objectID": "Introduction.html#questions-to-explore",
    "href": "Introduction.html#questions-to-explore",
    "title": "Introduction",
    "section": "Questions to Explore",
    "text": "Questions to Explore\n\n1. How did the ACA impact the pricing and accessibilities of prescription drugs in the United States?\n\n\n2. Have there been any significant changes related to drug pricing and the pharmaceutical industry since the ACA was passed?\n\n\n3. Has the pharmaceutical industry shown increasing profits since the ACA was established?\n\n\n4. Are there certain times of the year in which Americans may experience heightened drug costs?\n\n\n5. Does changes in pharmaceutical industry by ACA effect the death rate in the United States?\n\n\n6. What kind of connection can be drawns between the increased profitability of the U.S. pharmaceutical industry and rising out-of-pocket prescription drug costs for consumers?\n\n\n7. Can we predict the future prescription drug cost and out-of-pocket?\n\n\n8. Did the ACA successfull strike a balance between expanding healcare coverage and addressing concerns about rising drug costs?\n\n\n9. How does the ACA become controversial topic?\n\n\n10. What lessons can be learned from the ACA’s interaction with the pharmaceutical industry for future healthcare policy initiatives?"
  },
  {
    "objectID": "Introduction.html#aca-health-insurance-and-pharmaceutical-industry",
    "href": "Introduction.html#aca-health-insurance-and-pharmaceutical-industry",
    "title": "Introduction",
    "section": "",
    "text": "Why do we always hear people compare the United States and other countries health care system? Health insurance in the United States is always a problem governments and communities face. Compared to other countries, the U.S. does not have the flexibility and accessibility of the health care system for all citizens. Many Americans are paying out-of-pocket to access into medical system and some have no access. President Obama took this community challenge seriously and passed two laws to make a change in the healthcare system.\nThe Affordable Care Act (ACA) is the name for the comprehensive health care reform law and its amendments which addresses health insurance coverage, health care costs, and preventive care, also known as Obama care. Two laws significantly affect American health insurance: The Patient Protection and Affordable Care Act. Both laws are passed by President Barack Obama on March 23, 2010, and were amended by the Health Care and Education Reconciliation Act on March 30, 2010.\n\n\n\nACA\n\n\nThe ACA didn’t achieve its intended results as effectively as anticipated. As outlined by the American Action Forum, the ACA led to a direct hike in expenses for drug producers by introducing a new tax tied to the revenue from a company’s branded drug sales. While the overall prescription drug prices saw a reduction, the prices of branded prescription drugs experienced a rise. Between 2011 and 2015, this specific tax cost the pharmaceutical sector $14.1 billion. Additionally, the ACA extended Medicaid coverage to approximately 13 million Americans, mandated health insurance, and introduced new taxes on higher-income households to finance healthcare expenses, subsequently raising yearly premiums and out-of-pocket costs for numerous households."
  },
  {
    "objectID": "References.html",
    "href": "References.html",
    "title": "References",
    "section": "",
    "text": "https://www.americanprogress.org/article/big-pharma-reaps-profits-hurting-everyday-americans/\nhttps://www.proclinical.com/blogs/2023-7/the-top-10-pharmaceutical-companies-in-the-world-2023"
  },
  {
    "objectID": "Introduction.html#price-changes",
    "href": "Introduction.html#price-changes",
    "title": "Introduction",
    "section": "Price Changes",
    "text": "Price Changes\nMedical expenses, when paid directly by patients, place a heavy burden on families with moderate to low incomes. Many individuals in the U.S. avoid medical care unless it’s absolutely necessary due to these costs. These expenses aren’t limited to medications; they encompass deductibles, co-pays, and any fees not covered by insurance. Often, co-pays can amount to $30-$50. Furthermore, medicines for rare diseases or unique health conditions have witnessed consistent price hikes annually. This results in reduced medication intake, putting many at risk of avoidable health complications or even death.\nElevated prices for prescription drugs pose a financial strain for both patients and the health care system. The Office of the Assistant Secretary for Planning and Evaluation (ASPE) carried out a study to understand the trend in drug prices over time. In 2022, a noticeable spike in the cost of numerous drugs was observed, with an average increase of about $150 (10%) in January and $250 (7.8%) in July. Some medications experienced a staggering rise in prices, exceeding $20,000 or an increase of over 500%. Moreover, from July 2021 to July 2022, 1,216 products had price surges beyond the 8.5% inflation rate, averaging a hike of 31.6%. Data indicates that the ACA might not have a direct impact on the broader economy, which is why there’s an interest in examining its effects on the pharmaceutical sector and forecasting future prices."
  },
  {
    "objectID": "Introduction.html#pharmaceutical-companies",
    "href": "Introduction.html#pharmaceutical-companies",
    "title": "Introduction",
    "section": "Pharmaceutical Companies",
    "text": "Pharmaceutical Companies\nAs the US populace grapples with escalating costs of prescription medications, including essential drugs, major pharma corporations such as Pfizer and Johnson & Johnson, recognized for their role in supplying Covid-19 vaccines, continue to witness soaring yearly profits. The Center of American Progress (CAP) reports that these companies have hiked prices on their most-used drugs by a range of 40 to 71 percent between 2011 and 2015.\nIn this project, I will employ techniques like data collection, data preprocessing, clustering, feature reduction, decision tree methods encompassing both classification and regression, and association rule mining (ARM) in Python to delve into the transformations within the pharmaceutical sector and shifts in Medicaid health coverage post ACA implementation.\nTo explore the effect and impact by ACA across the nation, the following questions will be answered in this research. Each question will be addressed and answered with the backing of data throughout the project and in the conclusion with examples."
  },
  {
    "objectID": "References.html#article-references",
    "href": "References.html#article-references",
    "title": "References",
    "section": "",
    "text": "https://www.americanprogress.org/article/big-pharma-reaps-profits-hurting-everyday-americans/\nhttps://www.proclinical.com/blogs/2023-7/the-top-10-pharmaceutical-companies-in-the-world-2023"
  },
  {
    "objectID": "References.html#data-references",
    "href": "References.html#data-references",
    "title": "References",
    "section": "Data References:",
    "text": "Data References:\nhttps://gis.cdc.gov/GRASP/Fluview/FluHospRates.html\nhttps://finance.yahoo.com/quote/IHE/history?p=IHE\nhttps://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/projected"
  },
  {
    "objectID": "Code.html",
    "href": "Code.html",
    "title": "Code",
    "section": "",
    "text": "Click here to connect to GitHub classroom repo for codes."
  },
  {
    "objectID": "Data.html",
    "href": "Data.html",
    "title": "Data",
    "section": "",
    "text": "Click here to connect to GitHub classroom repo for row and cleaned data."
  },
  {
    "objectID": "Data_Gathering.html",
    "href": "Data_Gathering.html",
    "title": "Data Gathering",
    "section": "",
    "text": "A number of different sources of data were gathered worldwide initially for this research. These include data from the Centers for Medicare & Medicaid(CMS), Centers for Disease Control and Precention(CDC), and Yahoo Finance for stocks prices. Kaggle data is also extract for comparison between ACA and prescription drug costs.\n\n\nThe Centers for Medicare & Medicaid Services (CMS) operates under the U.S. Department of Health and Human Services and is responsible for managing key national healthcare initiatives. This includes the Medicare program, which offers health insurance to the elderly and certain disabled persons, and Medicaid, a joint state-federal initiative catering to specific low-income groups. Additionally, CMS supervises the Children’s Health Insurance Program (CHIP) and has significant involvement in the health insurance platforms established by the Affordable Care Act. Furthermore, it ensures adherence to quality benchmarks in facilities offering long-term care and other medical services.\nThe information on prescription drug expenses(out-of-pockets) was sourced from the National Health Expenditure Accounts maintained by the Centers for Medicare & Medicaid Services, which monitor diverse health expenditures in the U.S.\n\n\n\nClick logo to access the csv!\n\n\n\n\n\nThe Centers for Disease Control and Precention (CDC) operates as a key public health institution under the U.S. Department of Health and Human Services. Tasked with safeguarding public health, the CDC works diligently to manage and prevent illnesses, injuries, and impairments. It undertakes health studies, offers valuable health insights to inform decisions, and champions overall health and wellness. Additionally, it is pivotal in addressing health crises, such as disease outbreaks, and provides a broad spectrum of health recommendations.\nThe U.S. flu statistics 2019-2023 information comes from the CDC’s Regular Flu Monitoring Report that logs weekly figures for flu, pneumonia, and COVID-19 fatalities in the U.S. For this study, I concentrated on the weekly flu details, details of which will be elaborated on in subsequent sections.\n\n\n\nClick logo to access the csv!\n\n\n\n\n\nYahoo Finance is an online resource delivering a broad range of financial tools, updates, and information to its users and investors. It supplies up-to-the-minute stock values, fiscal updates, market reviews, and a collection of tools for investment. Managed by Yahoo!, this platform is a central hub for both casual investors and finance experts seeking market data, analytical tools, and insights on investments.\nThe information of ETF for Major U.S. Pharma Firms’ Stock was sourced from Yahoo Finance, detailing the stock value of the iShares U.S. Pharmaceuticals ETF, commonly known as IHE. This ETF mirrors the market behavior of the prominent U.S. drug manufacturing entities.\n\n\n\nClick logo to access the csv!\n\n\n\n\n\nKaggle, under Google’s umbrella, serves as a hub for data science aficionados and those passionate about machine learning. It grants access to diverse datasets for in-depth examination and insights.\nKeep in mind that Kaggle may not be the ideal platform for in-depth research project analyses. We utilize its data merely for comparison purposes and refrain from conducting extended evaluations with the dataset. We’ve sourced a dataset from Kaggle that details health insurance rates by state for the years 2010-2013 under the ACA.\n\n\n\nClick logo to access the csv!"
  },
  {
    "objectID": "Data_Gathering.html#centers-for-medicare-medicaid-servicescms",
    "href": "Data_Gathering.html#centers-for-medicare-medicaid-servicescms",
    "title": "Data Gathering",
    "section": "",
    "text": "The Centers for Medicare & Medicaid Services (CMS) operates under the U.S. Department of Health and Human Services and is responsible for managing key national healthcare initiatives. This includes the Medicare program, which offers health insurance to the elderly and certain disabled persons, and Medicaid, a joint state-federal initiative catering to specific low-income groups. Additionally, CMS supervises the Children’s Health Insurance Program (CHIP) and has significant involvement in the health insurance platforms established by the Affordable Care Act. Furthermore, it ensures adherence to quality benchmarks in facilities offering long-term care and other medical services.\nThe information on prescription drug expenses(out-of-pockets) was sourced from the National Health Expenditure Accounts maintained by the Centers for Medicare & Medicaid Services, which monitor diverse health expenditures in the U.S.\n\n\n\nClick logo to access the csv!"
  },
  {
    "objectID": "Data_Gathering.html#centers-for-disease-control-and-precention-cdc",
    "href": "Data_Gathering.html#centers-for-disease-control-and-precention-cdc",
    "title": "Data Gathering",
    "section": "",
    "text": "The Centers for Disease Control and Precention (CDC) operates as a key public health institution under the U.S. Department of Health and Human Services. Tasked with safeguarding public health, the CDC works diligently to manage and prevent illnesses, injuries, and impairments. It undertakes health studies, offers valuable health insights to inform decisions, and champions overall health and wellness. Additionally, it is pivotal in addressing health crises, such as disease outbreaks, and provides a broad spectrum of health recommendations.\nThe U.S. flu statistics 2019-2023 information comes from the CDC’s Regular Flu Monitoring Report that logs weekly figures for flu, pneumonia, and COVID-19 fatalities in the U.S. For this study, I concentrated on the weekly flu details, details of which will be elaborated on in subsequent sections.\n\n\n\nClick logo to access the csv!"
  },
  {
    "objectID": "Data_Gathering.html#yahoo-finance---etf-stock",
    "href": "Data_Gathering.html#yahoo-finance---etf-stock",
    "title": "Data Gathering",
    "section": "",
    "text": "Yahoo Finance is an online resource delivering a broad range of financial tools, updates, and information to its users and investors. It supplies up-to-the-minute stock values, fiscal updates, market reviews, and a collection of tools for investment. Managed by Yahoo!, this platform is a central hub for both casual investors and finance experts seeking market data, analytical tools, and insights on investments.\nThe information of ETF for Major U.S. Pharma Firms’ Stock was sourced from Yahoo Finance, detailing the stock value of the iShares U.S. Pharmaceuticals ETF, commonly known as IHE. This ETF mirrors the market behavior of the prominent U.S. drug manufacturing entities.\n\n\n\nClick logo to access the csv!"
  },
  {
    "objectID": "Data_Gathering.html#kaggle---aca-by-states",
    "href": "Data_Gathering.html#kaggle---aca-by-states",
    "title": "Data Gathering",
    "section": "",
    "text": "Kaggle, under Google’s umbrella, serves as a hub for data science aficionados and those passionate about machine learning. It grants access to diverse datasets for in-depth examination and insights.\nKeep in mind that Kaggle may not be the ideal platform for in-depth research project analyses. We utilize its data merely for comparison purposes and refrain from conducting extended evaluations with the dataset. We’ve sourced a dataset from Kaggle that details health insurance rates by state for the years 2010-2013 under the ACA.\n\n\n\nClick logo to access the csv!"
  },
  {
    "objectID": "Data_Cleaning.html",
    "href": "Data_Cleaning.html",
    "title": "Data Cleaning",
    "section": "",
    "text": "The data set sourced from CMS provides historical records of National Health Expenditures categorized by service type and funding source from 1960 to 2031. It encompasses details on national health spending, health consumption expenditures, personal health care, and other related health expenditure aspects. Our primary interest lies in the prescription drug expenditure data found between rows 82 and 89. Additionally, we’ll retain row 3 for the calendar years.\n\n\nCode\nimport pandas as pd\ncms_df = pd.read_csv(\"./row_data/NHE60-31.csv\")\n\nrow_to_keep = [1] + list(range(82,88))\n\ncms_filter = cms_df.iloc[row_to_keep]\n\ncms_filter.to_csv(\"./cleaned_data/cleaned_cms.csv\", index=False)\n\n\n\n\nCode\ncleaned_cms_df = pd.read_csv(\"./cleaned_data/cleaned_cms.csv\", skiprows=1)\ncleaned_cms_df.head()\n\n\n\n\n\n\n\n\n\nType of Service\nSource of Funds\n1960\n1961\n1962\n1963\n1964\n1965\n1966\n1967\n...\n2022\n2023\n2024\n2025\n2026\n2027\n2028\n2029\n2030\n2031\n\n\n\n\n0\nPrescription Drug Expenditures\nHealth Insurance\n37\n40\n44\n44\n80\n125\n277\n431\n...\n341565\n354231\n372163\n394771\n417446\n438986\n461133\n485676\n510090\n535423\n\n\n1\nPrescription Drug Expenditures\nPrivate Health Insurance\n33\n36\n40\n40\n76\n122\n171\n223\n...\n156369\n163237\n165469\n167360\n172249\n181615\n190783\n199554\n210305\n222727\n\n\n2\nPrescription Drug Expenditures\nMedicare\n0\n0\n0\n0\n0\n0\n0\n0\n...\n127310\n130035\n146107\n164274\n178704\n187425\n196918\n208832\n218364\n226920\n\n\n3\nPrescription Drug Expenditures\nMedicaid (Title XIX)\n0\n0\n0\n0\n0\n0\n103\n205\n...\n44669\n47258\n46500\n48716\n51738\n54846\n57972\n61458\n65201\n69153\n\n\n4\nPrescription Drug Expenditures\nOther Health Insurance\n4\n4\n4\n4\n4\n3\n3\n3\n...\n13218\n13701\n14087\n14421\n14755\n15101\n15460\n15833\n16220\n16622\n\n\n\n\n5 rows × 74 columns"
  },
  {
    "objectID": "Data_Cleaning.html#centers-for-medicare-medicaid-servicescms",
    "href": "Data_Cleaning.html#centers-for-medicare-medicaid-servicescms",
    "title": "Data Cleaning",
    "section": "",
    "text": "The data set sourced from CMS provides historical records of National Health Expenditures categorized by service type and funding source from 1960 to 2031. It encompasses details on national health spending, health consumption expenditures, personal health care, and other related health expenditure aspects. Our primary interest lies in the prescription drug expenditure data found between rows 82 and 89. Additionally, we’ll retain row 3 for the calendar years.\n\n\nCode\nimport pandas as pd\ncms_df = pd.read_csv(\"./row_data/NHE60-31.csv\")\n\nrow_to_keep = [1] + list(range(82,88))\n\ncms_filter = cms_df.iloc[row_to_keep]\n\ncms_filter.to_csv(\"./cleaned_data/cleaned_cms.csv\", index=False)\n\n\n\n\nCode\ncleaned_cms_df = pd.read_csv(\"./cleaned_data/cleaned_cms.csv\", skiprows=1)\ncleaned_cms_df.head()\n\n\n\n\n\n\n\n\n\nType of Service\nSource of Funds\n1960\n1961\n1962\n1963\n1964\n1965\n1966\n1967\n...\n2022\n2023\n2024\n2025\n2026\n2027\n2028\n2029\n2030\n2031\n\n\n\n\n0\nPrescription Drug Expenditures\nHealth Insurance\n37\n40\n44\n44\n80\n125\n277\n431\n...\n341565\n354231\n372163\n394771\n417446\n438986\n461133\n485676\n510090\n535423\n\n\n1\nPrescription Drug Expenditures\nPrivate Health Insurance\n33\n36\n40\n40\n76\n122\n171\n223\n...\n156369\n163237\n165469\n167360\n172249\n181615\n190783\n199554\n210305\n222727\n\n\n2\nPrescription Drug Expenditures\nMedicare\n0\n0\n0\n0\n0\n0\n0\n0\n...\n127310\n130035\n146107\n164274\n178704\n187425\n196918\n208832\n218364\n226920\n\n\n3\nPrescription Drug Expenditures\nMedicaid (Title XIX)\n0\n0\n0\n0\n0\n0\n103\n205\n...\n44669\n47258\n46500\n48716\n51738\n54846\n57972\n61458\n65201\n69153\n\n\n4\nPrescription Drug Expenditures\nOther Health Insurance\n4\n4\n4\n4\n4\n3\n3\n3\n...\n13218\n13701\n14087\n14421\n14755\n15101\n15460\n15833\n16220\n16622\n\n\n\n\n5 rows × 74 columns"
  },
  {
    "objectID": "Data_Cleaning.html#centers-for-disease-control-and-precention-cdc",
    "href": "Data_Cleaning.html#centers-for-disease-control-and-precention-cdc",
    "title": "Data Cleaning",
    "section": "Centers for Disease Control and Precention (CDC)",
    "text": "Centers for Disease Control and Precention (CDC)\nThe CDC’s dataset provides specifics on Influenza Hospitalization Rates (per 100,000 population) from the FluSurv-NET Network, as of October 9, 2023. The dataset encompasses details such as influenza type, calendar years and weeks, gender, race, influenza rates, and additional related data. We aim to choose columns that highlight calendar data, cumulative rates, and weekly rates. For data cleansing, we intend to omit columns 1, 2, 6, 7, and 8.\n\n\nCode\ncdc_df = pd.read_csv(\"./row_data/FluSurveillance_Custom_Download_Data 12.51.34 AM.csv\", skiprows=2)\n\ncdc_df.drop(cdc_df.columns[[0,1,5,6,7]], axis=1, inplace=True)\n\ncdc_df.to_csv(\"./cleaned_data/cleaned_cdc.csv\", index=False)\ncdc_df.head()\n\n\n\n\n\n\n\n\n\nYEAR\nMMWR-YEAR\nMMWR-WEEK\nCUMULATIVE RATE\nWEEKLY RATE\n\n\n\n\n0\n2019-20\n2019.0\n40.0\n0.1\n0.1\n\n\n1\n2019-20\n2019.0\n40.0\n0.1\n0.1\n\n\n2\n2019-20\n2019.0\n40.0\n0.1\n0.1\n\n\n3\n2019-20\n2019.0\n40.0\n0.2\n0.2\n\n\n4\n2019-20\n2019.0\n40.0\n0.0\n0.0"
  },
  {
    "objectID": "Data_Cleaning.html#yahoo-finance---etf-stock",
    "href": "Data_Cleaning.html#yahoo-finance---etf-stock",
    "title": "Data Cleaning",
    "section": "Yahoo Finance - ETF Stock",
    "text": "Yahoo Finance - ETF Stock\nThe dataset from Yahoo Finance provides detailed information on IHE stock market data from October 2019 to October 2023. It includes data on opening, closing, highest, lowest, adjusted closing prices, and volume of IHE stocks. There is no need for data cleaning, as all columns and rows are meticulously curated by Yahoo Finance. The provided information is readily available for visualization and further analysis.\n\n\nCode\nIHE_df = pd.read_csv(\"./row_data/IHE.csv\")\n\nIHE_df.to_csv(\"./cleaned_data/IHE.csv\", index=False)\n\nIHE_df.head()\n\n\n\n\n\n\n\n\n\nDate\nOpen\nHigh\nLow\nClose\nAdj Close\nVolume\n\n\n\n\n0\n2019-10-09\n137.729996\n138.389999\n137.729996\n138.059998\n129.229935\n7600\n\n\n1\n2019-10-10\n137.729996\n138.539993\n137.729996\n138.059998\n129.229935\n6300\n\n\n2\n2019-10-11\n139.490005\n141.050003\n139.490005\n140.119995\n131.158127\n19200\n\n\n3\n2019-10-14\n139.720001\n140.369995\n139.720001\n139.789993\n130.849258\n4500\n\n\n4\n2019-10-15\n141.110001\n142.889999\n141.110001\n142.429993\n133.320389\n193500"
  },
  {
    "objectID": "Data_Cleaning.html#kaggle---aca-by-states",
    "href": "Data_Cleaning.html#kaggle---aca-by-states",
    "title": "Data Cleaning",
    "section": "Kaggle - ACA by States",
    "text": "Kaggle - ACA by States\nThe Kaggle dataset provides state-by-state information on the ACA, including the uninsured rate, changes in uninsured rates, shifts in health insurance coverage, market health insurance details, and other insights into ACA-induced changes in the health insurance sector. Within this dataset, there are certain missing entries and columns that are not necessary for our visualization, which we’ll be discarding.\n\n\nCode\naca_df = pd.read_csv(\"./row_data/states.csv\")\n\naca_df.drop(aca_df.columns[[5,6,7,8,9]], axis=1, inplace=True)\n\naca_df.to_csv(\"./cleaned_data/cleaned_states.csv\", index=False)\n\naca_df.head()\n\n\n\n\n\n\n\n\n\nState\nUninsured Rate (2010)\nUninsured Rate (2015)\nUninsured Rate Change (2010-2015)\nHealth Insurance Coverage Change (2010-2015)\nMedicaid Enrollment (2013)\nMedicaid Enrollment (2016)\nMedicaid Enrollment Change (2013-2016)\nMedicare Enrollment (2016)\n\n\n\n\n0\nAlabama\n0.146\n0.101\n-0.045\n215000\n799176.0\n910775\n111599.0\n989855\n\n\n1\nAlaska\n0.199\n0.149\n-0.050\n36000\n122334.0\n166625\n44291.0\n88966\n\n\n2\nArizona\n0.169\n0.108\n-0.061\n410000\n1201770.0\n1716198\n514428.0\n1175624\n\n\n3\nArkansas\n0.175\n0.095\n-0.080\n234000\n556851.0\n920194\n363343.0\n606146\n\n\n4\nCalifornia\n0.185\n0.086\n-0.099\n3826000\n7755381.0\n11843081\n4087700.0\n5829777"
  },
  {
    "objectID": "textNB.html",
    "href": "textNB.html",
    "title": "Feature Selection for Text Data",
    "section": "",
    "text": "In this segment, we will implement the Naive Bayes technique, specifically tailored for text data. The dataset at hand is sourced from NewsAPI and revolves around various topics, with an additional ‘category’ column incorporated to facilitate our analysis. Our focus will be narrowed down to the initial 10 documents, aiming to evaluate the model’s accuracy and its effectiveness in accurately classifying certain articles.\nTo commence, we will embark on a comprehensive data cleaning process, ensuring that our text data is free from any inconsistencies or unwanted characters that could potentially skew our results. Following this, we will proceed to divide our dataset into training and test sets. This critical step allows us to train our model on one subset of the data and validate its performance on another, ensuring that our evaluations are robust and reliable.\nThrough this meticulous approach, we aim to enhance the performance of our Naive Bayes model, providing us with insightful and accurate classifications of the news articles based on their content.\nCode\nimport numpy as np \nimport seaborn as sns\nimport pandas as pd\nimport matplotlib.pyplot as plt\nimport scipy\nimport sklearn \n\nfrom sklearn.model_selection import train_test_split\nfrom sklearn.feature_extraction.text import TfidfVectorizer\nfrom sklearn.naive_bayes import MultinomialNB\nfrom sklearn.pipeline import make_pipeline\nfrom sklearn import metrics\n\nfrom sklearn.feature_extraction.text import CountVectorizer\nfrom sklearn.metrics import classification_report, accuracy_score\nCode\ntext_df = pd.read_csv(\"cleaned_data/medicine-cleaned.csv\")\n\ntext_df.head() #we are only focusing on the first 10 rows\n\n\n\n\n\n\n\n\n\ntitle\ndescription\n\n\n\n\n0\na round-up of the talks from gaconf usa 2023\ngaconf returned to the us this week with a ser...\n\n\n1\namerican can prevent (and control) type 2 diab...\nusa today's health team spoke with scores of e...\n\n\n2\nthe steep cost of type 2: when diabetes dragge...\nthe nation's disjointed and confusing health c...\n\n\n3\na hidden system of exploitation underpins us h...\nthis series was produced in partnership with t...\n\n\n4\nthe childcare cliff: $122 billion dollar crisi...\nthe childcare crisis in america; the harsh tru...\nFirst, we want to eliminate to first 10 rows of dataset.\nCode\ntext_df = text_df.iloc[:10]\nlen(text_df)\n\ntext_df['category'] = [0, 1, 1, 2, 2, 3, 3, 4, 4, 5] \ntext_df.head()\n\n\n\n\n\n\n\n\n\ntitle\ndescription\ncategory\n\n\n\n\n0\na round-up of the talks from gaconf usa 2023\ngaconf returned to the us this week with a ser...\n0\n\n\n1\namerican can prevent (and control) type 2 diab...\nusa today's health team spoke with scores of e...\n1\n\n\n2\nthe steep cost of type 2: when diabetes dragge...\nthe nation's disjointed and confusing health c...\n1\n\n\n3\na hidden system of exploitation underpins us h...\nthis series was produced in partnership with t...\n2\n\n\n4\nthe childcare cliff: $122 billion dollar crisi...\nthe childcare crisis in america; the harsh tru...\n2"
  },
  {
    "objectID": "textNB.html#train-and-test-dataset",
    "href": "textNB.html#train-and-test-dataset",
    "title": "Feature Selection for Text Data",
    "section": "Train and Test Dataset",
    "text": "Train and Test Dataset\nNow, we are transitioning into a crucial phase of our analysis: partitioning our dataset into training and test subsets. This is a pivotal step when preparing to apply the Naive Bayes algorithm specifically to text data.\nThe rationale behind this split is to ensure that we have a separate set of data on which to train our model (the training set), and another distinct set to evaluate its performance (the test set). By adopting this approach, we can accurately assess how well our model generalizes to unseen data, ensuring the robustness and reliability of our results.\nFollowing this data split, we will be well-prepared to implement the Naive Bayes algorithm on our text data, striving for a model that delivers accurate and insightful predictions, thereby enhancing our understanding of the dataset at hand.\n\n\nCode\nX_train, X_test, y_train, y_test = train_test_split(text_df[['title', 'description']], text_df['category'], test_size=0.2, random_state=42)\n\nX_train['text'] = X_train['title'] + ' ' + X_train['description']\nX_test['text'] = X_test['title'] + ' ' + X_test['description']"
  },
  {
    "objectID": "textNB.html#vectorization",
    "href": "textNB.html#vectorization",
    "title": "Feature Selection for Text Data",
    "section": "Vectorization",
    "text": "Vectorization\nLeveraging text data necessitates its transformation into a numerical format, a process known as Text Vectorization, which is crucial for compatibility with machine learning algorithms. Text Vectorization intricately converts textual content into numerical values, creating a structured and analyzable representation of the dataset. This transformation not only facilitates the application of algorithms like Naive Bayes but also enhances the model’s capability to discern patterns and make predictions based on textual inputs. By adopting text vectorization, we bridge the gap between the rich, unstructured data present in text form and the numerical prerequisites of machine learning models, setting the stage for a more accurate and insightful analytical experience.\n\n\nCode\nvectorizer = CountVectorizer()\nX_train_vect = vectorizer.fit_transform(X_train['text'])\nX_test_vect = vectorizer.transform(X_test['text'])"
  },
  {
    "objectID": "textNB.html#model-training",
    "href": "textNB.html#model-training",
    "title": "Feature Selection for Text Data",
    "section": "Model Training",
    "text": "Model Training\nUpon the successful vectorization of our text data, transforming our textual content into numerical format suitable for machine learning, we seamlessly transition into the Model Training phase. In this critical stage, we employ a Naive Bayes classifier, meticulously trained using our meticulously prepared text data. This probabilistic model, renowned for its efficacy in handling text classification tasks, learns the underlying patterns and associations between the words and their respective categories from the training dataset. By so doing, it equips itself to make informed and accurate predictions on unseen data, showcasing its potential to serve as a robust tool in text-based classification endeavors.\n\n\nCode\nclassify = MultinomialNB()\nclassify.fit(X_train_vect, y_train)\n\n\nMultinomialNB()In a Jupyter environment, please rerun this cell to show the HTML representation or trust the notebook. On GitHub, the HTML representation is unable to render, please try loading this page with nbviewer.org.MultinomialNBMultinomialNB()"
  },
  {
    "objectID": "textNB.html#prediction",
    "href": "textNB.html#prediction",
    "title": "Feature Selection for Text Data",
    "section": "Prediction",
    "text": "Prediction\nWith our data now meticulously partitioned into training and testing sets, we are poised to apply the MultinomialNB() classifier, a variant of Naive Bayes specifically tailored for multinomially distributed data, which is often the case with text. By utilizing this classifier, we aim to make predictions on our test data. Lastly, we can simply calculateaccuracy and print classification report using prediction value.\n\n\nCode\ny_predict = classify.predict(X_test_vect)\n\n\n\n\nCode\nprint('Accuracy:', accuracy_score(y_test, y_predict))\n\nprint('Classification Report:\\n', classification_report(y_test, y_predict))\n\n\nAccuracy: 0.5\nClassification Report:\n               precision    recall  f1-score   support\n\n           1       1.00      1.00      1.00         1\n           2       0.00      0.00      0.00         0\n           4       0.00      0.00      0.00         1\n\n    accuracy                           0.50         2\n   macro avg       0.33      0.33      0.33         2\nweighted avg       0.50      0.50      0.50         2\n\n\n\n/Users/naomiyamaguchi/Library/r-miniconda/lib/python3.10/site-packages/sklearn/metrics/_classification.py:1469: UndefinedMetricWarning: Precision and F-score are ill-defined and being set to 0.0 in labels with no predicted samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n/Users/naomiyamaguchi/Library/r-miniconda/lib/python3.10/site-packages/sklearn/metrics/_classification.py:1469: UndefinedMetricWarning: Recall and F-score are ill-defined and being set to 0.0 in labels with no true samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n/Users/naomiyamaguchi/Library/r-miniconda/lib/python3.10/site-packages/sklearn/metrics/_classification.py:1469: UndefinedMetricWarning: Precision and F-score are ill-defined and being set to 0.0 in labels with no predicted samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n/Users/naomiyamaguchi/Library/r-miniconda/lib/python3.10/site-packages/sklearn/metrics/_classification.py:1469: UndefinedMetricWarning: Recall and F-score are ill-defined and being set to 0.0 in labels with no true samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n/Users/naomiyamaguchi/Library/r-miniconda/lib/python3.10/site-packages/sklearn/metrics/_classification.py:1469: UndefinedMetricWarning: Precision and F-score are ill-defined and being set to 0.0 in labels with no predicted samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))\n/Users/naomiyamaguchi/Library/r-miniconda/lib/python3.10/site-packages/sklearn/metrics/_classification.py:1469: UndefinedMetricWarning: Recall and F-score are ill-defined and being set to 0.0 in labels with no true samples. Use `zero_division` parameter to control this behavior.\n  _warn_prf(average, modifier, msg_start, len(result))"
  },
  {
    "objectID": "textNB.html#conclusion",
    "href": "textNB.html#conclusion",
    "title": "Feature Selection for Text Data",
    "section": "Conclusion",
    "text": "Conclusion\nIn conclusion, applying the Naive Bayes classifier to text data in Python encompasses critical stages such as data preprocessing, which entails refining the text for the algorithms; text vectorization, which transforms the text into a machine-readable numerical format; and model training, where the classifier is taught using the processed data. Following these steps is the evaluation of the model’s performance, which might reveal a lower-than-anticipated accuracy. However, this accuracy can potentially be improved by adjusting categories and experimenting with various text datasets, indicating that the model’s effectiveness is contingent upon the nature and quality of the data it is fed."
  },
  {
    "objectID": "NB.html",
    "href": "NB.html",
    "title": "Naïve Bayes",
    "section": "",
    "text": "In this section, we are going to explore Naïve Bayes (NB)\n\n\nNaïve Bayes is a probabilistic classification method rooted in applying Bayes’ theorem, with an emphasis on the “naïve” assumption of independence between features. This means that for the purpose of classification, each feature contributes independently to the probability of a particular class, regardless of the values of other features.\n\n\n\nNaïve Bayes estimates the posterior probability of a class given a set of features using Bayes’ theorem. Let’s denote \\(x\\) as feature and \\(C_k\\) as class. Formula can be written as: \\[P(C_k|x) = \\frac{P(x|C_k) \\cdot P(C_k)}{P(x)}\\] Where:\n\n\\(P(C_k|x)\\) is the posterior probability of class \\(C_k\\) given features x.\n\\(P(x|C_k)\\) is the likelihood which the probability of features x given class \\(C_k\\).\n\\(P(C_k)\\) is the prior probability of class \\(C_k\\).\n\\(P(x)\\) is the prior probability of features x.\n\nNote: \\(P(x)\\) is constant for all classes, it’s often omitted in practice, and the classification becomes about finding the class \\(C_k\\) that maximizes the numerator.\n\n\n\nThe primary objective of Naive Bayes classification is to determine the most probable class for a given instance based on its features. By leveraging the power of probability and statistics, the algorithm aims to provide an accurate and computationally efficient classification mechanism.\nBy using Naïve Bayes classification, we want to:\n-Predict the class of an instance based on its features with a high level of accuracy.\n-Offer a simple yet effective model, especially for datasets with many features or large datasets where other algorithms might be computationally intensive.\n-Handle both continuous and discrete data through its various variants.\n\n\n\nGaussian Naïve Bayes:\n-Used when features are continuous and follow a Gaussian or normal distribution.\n-It assumes that the values associated with each class are distributed according to a Gaussian distribution.\n-Choose Gaussian when dealing with continuous data that’s normally distributed.\nMultinomial Naïve Bayes:\n-Appropriate for discrete counts.\n-Often used for text classification where the features are the frequency of words (or n-grams) in documents.\n-Choose Multinomial when working with discrete data, especially in applications like text analytics where you’re counting word occurrences.\nBernoulli Naïve Bayes:\n-Works with binary/boolean features.\n-Useful in text classification tasks where features represent the presence or absence of a word.\n-Choose Bernoulli for binary data, or when modeling binary features in datasets, such as “word exists or not” in text classification.\nIn conclusion, Naïve Bayes is a versatile and probabilistic classification method offering simplicity and efficiency, especially in high-dimensional datasets. It’s paramount to select the appropriate variant based on the nature of your data to ensure optimal results.\nIn this segment, we will be applying the Naive Bayes algorithm to both labeled records and textual data. Analogous to our work in Exploratory Data Analysis (EDA), we will utilize the IHE stock market dataset for the labeled records. For the textual data, we will extract information from the NewsAPI, which we interacted with in a prior lab session. Detailed descriptions and characteristics of these datasets can be found under the ‘Small Data’ and ‘Large Data’ tabs, respectively."
  },
  {
    "objectID": "NB.html#overview-objective",
    "href": "NB.html#overview-objective",
    "title": "Naïve Bayes",
    "section": "",
    "text": "Naïve Bayes is a probabilistic classification method rooted in applying Bayes’ theorem, with an emphasis on the “naïve” assumption of independence between features. This means that for the purpose of classification, each feature contributes independently to the probability of a particular class, regardless of the values of other features."
  },
  {
    "objectID": "NB.html#probabilistic-nature-and-bayes-theorem",
    "href": "NB.html#probabilistic-nature-and-bayes-theorem",
    "title": "Naïve Bayes",
    "section": "",
    "text": "Naïve Bayes estimates the posterior probability of a class given a set of features using Bayes’ theorem. Let’s denote \\(x\\) as feature and \\(C_k\\) as class. Formula can be written as: \\[P(C_k|x) = \\frac{P(x|C_k) \\cdot P(C_k)}{P(x)}\\] Where:\n\n\\(P(C_k|x)\\) is the posterior probability of class \\(C_k\\) given features x.\n\\(P(x|C_k)\\) is the likelihood which the probability of features x given class \\(C_k\\).\n\\(P(C_k)\\) is the prior probability of class \\(C_k\\).\n\\(P(x)\\) is the prior probability of features x.\n\nNote: \\(P(x)\\) is constant for all classes, it’s often omitted in practice, and the classification becomes about finding the class \\(C_k\\) that maximizes the numerator."
  },
  {
    "objectID": "NB.html#objectives-aim",
    "href": "NB.html#objectives-aim",
    "title": "Naïve Bayes",
    "section": "",
    "text": "The primary objective of Naive Bayes classification is to determine the most probable class for a given instance based on its features. By leveraging the power of probability and statistics, the algorithm aims to provide an accurate and computationally efficient classification mechanism.\nBy using Naïve Bayes classification, we want to:\n-Predict the class of an instance based on its features with a high level of accuracy.\n-Offer a simple yet effective model, especially for datasets with many features or large datasets where other algorithms might be computationally intensive.\n-Handle both continuous and discrete data through its various variants."
  },
  {
    "objectID": "NB.html#variants-of-naïve-bayes",
    "href": "NB.html#variants-of-naïve-bayes",
    "title": "Naïve Bayes",
    "section": "",
    "text": "Gaussian Naïve Bayes:\n-Used when features are continuous and follow a Gaussian or normal distribution.\n-It assumes that the values associated with each class are distributed according to a Gaussian distribution.\n-Choose Gaussian when dealing with continuous data that’s normally distributed.\nMultinomial Naïve Bayes:\n-Appropriate for discrete counts.\n-Often used for text classification where the features are the frequency of words (or n-grams) in documents.\n-Choose Multinomial when working with discrete data, especially in applications like text analytics where you’re counting word occurrences.\nBernoulli Naïve Bayes:\n-Works with binary/boolean features.\n-Useful in text classification tasks where features represent the presence or absence of a word.\n-Choose Bernoulli for binary data, or when modeling binary features in datasets, such as “word exists or not” in text classification.\nIn conclusion, Naïve Bayes is a versatile and probabilistic classification method offering simplicity and efficiency, especially in high-dimensional datasets. It’s paramount to select the appropriate variant based on the nature of your data to ensure optimal results.\nIn this segment, we will be applying the Naive Bayes algorithm to both labeled records and textual data. Analogous to our work in Exploratory Data Analysis (EDA), we will utilize the IHE stock market dataset for the labeled records. For the textual data, we will extract information from the NewsAPI, which we interacted with in a prior lab session. Detailed descriptions and characteristics of these datasets can be found under the ‘Small Data’ and ‘Large Data’ tabs, respectively."
  },
  {
    "objectID": "text_data.html",
    "href": "text_data.html",
    "title": "",
    "section": "",
    "text": "CodeShow All CodeHide All Code\n\n\n\n\n\nCode\nAPI_KEY=\"695bba0b702f4443ac5ee2022411804f\"\n\nimport requests\nimport json\nimport re\nimport pandas as pd\nfrom sklearn.feature_extraction.text import CountVectorizer\n\n\n\n\nCode\nbaseURL = \"https://newsapi.org/v2/everything?\"\ntotal_requests=2\nverbose=True\n\ntopic_1 = 'medical cost USA'\n\nURLpost_1 = {'apiKey': API_KEY,\n            'q': '+'+topic_1,\n            'sortBy': 'relevancy',\n            'totalRequests': 1}\n\nresponse_1 = requests.get(baseURL, URLpost_1) #request data from the server\nresponse_1 = response_1.json() #extract txt data from request into json\n\n# #GET TIMESTAMP FOR PULL REQUEST\nfrom datetime import datetime\ntimestamp = datetime.now().strftime(\"%Y-%m-%d-H%H-M%M-S%S\")\n\n# SAVE TO FILE \nwith open(timestamp+'-newapi-medicine-raw-data.json', 'w') as outfile:\n    json.dump(response_1, outfile, indent=4)\n \n \n\ndef string_cleaner(input_string):\n    try: \n        out=re.sub(r\"\"\"\n                    [,.;@#?!&$-]+  # Accept one or more copies of punctuation\n                    \\ *           # plus zero or more copies of a space,\n                    \"\"\",\n                    \" \",          # and replace it with a single space\n                    input_string, flags=re.VERBOSE)\n\n        #REPLACE SELECT CHARACTERS WITH NOTHING\n        out = re.sub('[’.]+', '', input_string)\n\n        #ELIMINATE DUPLICATE WHITESPACES USING WILDCARDS\n        out = re.sub(r'\\s+', ' ', out)\n\n        #CONVERT TO LOWER CASE\n        out=out.lower()\n    except:\n        print(\"ERROR\")\n        out=''\n    return out\narticle_list_1 =response_1['articles']   #list of dictionaries for each article\narticle_keys_1=article_list_1[0].keys()\nprint(\"AVAILABLE KEYS:\")\nprint(article_keys_1)\nindex=0\ncleaned_data_1=[];  \n\nfor article in article_list_1:\n    tmp=[]\n    if(verbose):\n        print(\"#------------------------------------------\")\n        print(\"#\",index)\n        print(\"#------------------------------------------\")\n\n    for key in article_keys_1:\n        if(verbose):\n            print(\"----------------\")\n            print(key)\n            print(article[key])\n            print(\"----------------\")\n\n        if(key=='source'):\n            src=string_cleaner(article[key]['name'])\n            tmp.append(src) \n\n        if(key=='author'):\n            author=string_cleaner(article[key])\n            #ERROR CHECK (SOMETIMES AUTHOR IS SAME AS PUBLICATION)\n            if(src in author): \n                print(\" AUTHOR ERROR:\",author);author='NA'\n            tmp.append(author)\n\n        if(key=='title'):\n            tmp.append(string_cleaner(article[key]))\n\n        if(key=='description'):\n            tmp.append(string_cleaner(article[key]))\n\n        # if(key=='content'):\n        #     tmp.append(string_cleaner(article[key]))\n\n        if(key=='publishedAt'):\n            #DEFINE DATA PATERN FOR RE TO CHECK  .* --&gt; wildcard\n            ref = re.compile('.*-.*-.*T.*:.*:.*Z')\n            date=article[key]\n            if(not ref.match(date)):\n                print(\" DATE ERROR:\",date); date=\"NA\"\n            tmp.append(date)\n\n    cleaned_data_1.append(tmp)\n    index+=1   \n\n\ndf_1 = pd.DataFrame(cleaned_data_1, columns = ['src', 'author', 'title', 'description', 'url'])\ndf_1 = df_1[['title', 'description']]\ndf_1.to_csv('medicine-cleaned.csv', index=False)\ndf_1.head()\n\n\nAVAILABLE KEYS:\ndict_keys(['source', 'author', 'title', 'description', 'url', 'urlToImage', 'publishedAt', 'content'])\n#------------------------------------------\n# 0\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Eurogamer.net'}\n----------------\n----------------\nauthor\nGeoffrey Bunting\n----------------\n----------------\ntitle\nA round-up of the talks from GAconf USA 2023\n----------------\n----------------\ndescription\nGAconf returned to the US this week with a series of accessibility talks hosted at the Archer Hotel in Redmond, Washington. Virtual attendance was available through Zoom and YouTube. Talks ranged from those on personal experiences of disability and accessibil…\n----------------\n----------------\nurl\nhttps://www.eurogamer.net/a-round-up-of-the-talks-from-gaconf-usa-2023\n----------------\n----------------\nurlToImage\nhttps://assetsio.reedpopcdn.com/FORZA-SITE_QkZV9pp.jpg?width=1200&height=630&fit=crop&enable=upscale&auto=webp\n----------------\n----------------\npublishedAt\n2023-10-18T09:00:00Z\n----------------\n----------------\ncontent\nGAconf returned to the US this week with a series of accessibility talks hosted at the Archer Hotel in Redmond, Washington. Virtual attendance was available through Zoom and YouTube. Talks ranged fro… [+6476 chars]\n----------------\n#------------------------------------------\n# 1\n#------------------------------------------\n----------------\nsource\n{'id': 'usa-today', 'name': 'USA Today'}\n----------------\n----------------\nauthor\nKaren Weintraub and Adrianna Rodriguez, USA TODAY\n----------------\n AUTHOR ERROR: karen weintraub and adrianna rodriguez, usa today\n----------------\ntitle\nAmerican can prevent (and control) Type 2 diabetes. So why aren’t we doing it?\n----------------\n----------------\ndescription\nUSA TODAY's Health team spoke with scores of experts to understand why, despite solutions, more Americans continue to struggle with Type 2 diabetes.\n----------------\n----------------\nurl\nhttps://www.usatoday.com/story/news/health/2023/10/01/type-2-diabetes-prevention-progress/70768126007/\n----------------\n----------------\nurlToImage\nhttps://s.yimg.com/ny/api/res/1.2/mMu7qCOLE8amNbJzVAgUlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/usa_today_news_641/560f8f2f66ba7da394152ec23bf58af5\n----------------\n----------------\npublishedAt\n2023-10-01T09:01:34Z\n----------------\n----------------\ncontent\nEditor's note: Part one of a five-part USA TODAY series revealing why America hasn't solved its long struggle with Type 2 diabetes.\nFor chef Robin Ray, newly married with young stepchildren, the tur… [+19198 chars]\n----------------\n#------------------------------------------\n# 2\n#------------------------------------------\n----------------\nsource\n{'id': 'usa-today', 'name': 'USA Today'}\n----------------\n----------------\nauthor\nAdrianna Rodriguez, USA TODAY\n----------------\n AUTHOR ERROR: adrianna rodriguez, usa today\n----------------\ntitle\nThe steep cost of Type 2: When diabetes dragged her down, she chose to fight\n----------------\n----------------\ndescription\nThe nation's disjointed and confusing health care system leaves many Type 2 diabetes patients to navigate it with little support.\n----------------\n----------------\nurl\nhttps://www.usatoday.com/story/news/health/2023/10/01/managing-type-2-diabetes/70785333007/\n----------------\n----------------\nurlToImage\nhttps://s.yimg.com/ny/api/res/1.2/Kzfcu.H2Hl9m_mpf3_pg6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/usa_today_news_641/07fa085fc3b2d5a45d5a9facef8f1293\n----------------\n----------------\npublishedAt\n2023-10-01T09:02:16Z\n----------------\n----------------\ncontent\nEditor's note: Part four of a five-part USA TODAY series revealing why America hasn't solved its long struggle with Type 2 diabetes.\nPHILADELPHIA Sunflowers are everywhere in Keenya Taylors cozy nor… [+17011 chars]\n----------------\n#------------------------------------------\n# 3\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Quartz India'}\n----------------\n----------------\nauthor\nAurora Almendral\n----------------\n----------------\ntitle\nA hidden system of exploitation underpins US hospitals’ employment of foreign nurses\n----------------\n----------------\ndescription\nThis series was produced in partnership with the nonprofit newsroom Type Investigations, with support from the Gertrude Blumenthal Kasbekar Fund, the Puffin Foundation, and the Pulitzer Center.Read more...\n----------------\n----------------\nurl\nhttps://qz.com/a-hidden-system-of-exploitation-underpins-us-hospitals-1850888315\n----------------\n----------------\nurlToImage\nhttps://i.kinja-img.com/image/upload/c_fill,f_auto,fl_progressive,g_center,h_675,pg_1,q_80,w_1200/b429e6d685c5960fb65cdd434e0d3ad8.jpg\n----------------\n----------------\npublishedAt\n2023-10-02T20:38:00Z\n----------------\n----------------\ncontent\nThis series was produced in partnership with the nonprofit newsroom Type Investigations, with support from the Gertrude Blumenthal Kasbekar Fund, the Puffin Foundation, and the Pulitzer Center.\nTALL… [+34835 chars]\n----------------\n#------------------------------------------\n# 4\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Forbes'}\n----------------\n----------------\nauthor\nGemma Allen, Contributor, \n Gemma Allen, Contributor\n https://www.forbes.com/sites/gemmaallen/\n----------------\n AUTHOR ERROR: gemma allen, contributor, gemma allen, contributor https://wwwforbescom/sites/gemmaallen/\n----------------\ntitle\nThe Childcare Cliff: $122 Billion Dollar Crisis, But Whose Problem Is It?\n----------------\n----------------\ndescription\nThe childcare crisis in America; the harsh truth of systemic inequality, peculiar economics and lack of support for a industry at the backbone of the economy.\n----------------\n----------------\nurl\nhttps://www.forbes.com/sites/gemmaallen/2023/09/30/the-childcare-cliff-122-billion-dollar-crisis-but-whose-problem-is-it/\n----------------\n----------------\nurlToImage\nhttps://imageio.forbes.com/specials-images/imageserve/6518d76d9cb241ef5b2c36b1/0x0.jpg?format=jpg&width=1200\n----------------\n----------------\npublishedAt\n2023-10-01T03:40:41Z\n----------------\n----------------\ncontent\nWASHINGTON, D.C. - APRIL 20, 2018: A daycare center employee pushes a KinderVan filled with ... [+] preschool children on an outing along the National Mall in Washington, D.C. (Photo by Robert Alexan… [+8508 chars]\n----------------\n#------------------------------------------\n# 5\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Forbes'}\n----------------\n----------------\nauthor\nAvivah Wittenberg-Cox, Contributor, \n Avivah Wittenberg-Cox, Contributor\n https://www.forbes.com/sites/avivahwittenbergcox/\n----------------\n AUTHOR ERROR: avivah wittenberg-cox, contributor, avivah wittenberg-cox, contributor https://wwwforbescom/sites/avivahwittenbergcox/\n----------------\ntitle\n‘Mad Men’ Meets Medicine - #MeToo Hits The UK’s National Health Service\n----------------\n----------------\ndescription\nNew report reveals one in three female surgeons in the UK suffer sexual harassment. Women start to organise - at a Women in Medicine conference.\n----------------\n----------------\nurl\nhttps://www.forbes.com/sites/avivahwittenbergcox/2023/10/06/mad-men-meets-medicinemetoo-hits-the-uks-national-health-service/\n----------------\n----------------\nurlToImage\nhttps://imageio.forbes.com/specials-images/imageserve/651fece0737457425b914359/0x0.jpg?format=jpg&width=1200\n----------------\n----------------\npublishedAt\n2023-10-06T12:03:27Z\n----------------\n----------------\ncontent\nDrs. Helen Burdett and Kate Stannard, Founders of Women in Medicine (WIMIN)\nKS\nA conference dedicated to women in medicine, WIMIN, came hard on the heels of a much-publicised report on sexism in su… [+9747 chars]\n----------------\n#------------------------------------------\n# 6\n#------------------------------------------\n----------------\nsource\n{'id': 'newsweek', 'name': 'Newsweek'}\n----------------\n----------------\nauthor\nSuzanne Blake\n----------------\n----------------\ntitle\nSocial Security Update: How Much 2024 Payments Are Expected To Increase\n----------------\n----------------\ndescription\nThe cost of living adjustment rose by 3.2 percent for 2024, the Social Security Administration announced on Thursday.\n----------------\n----------------\nurl\nhttps://www.newsweek.com/cost-living-adjustment-increase-seniors-social-security-1834019\n----------------\n----------------\nurlToImage\nhttps://d.newsweek.com/en/full/2293457/social-security.jpg\n----------------\n----------------\npublishedAt\n2023-10-12T13:13:46Z\n----------------\n----------------\ncontent\nThe cost of living adjustment rose by 3.2 percent for 2024, the Social Security Administration announced today. This marks a major shift down from the current year's increase of 8.7 percent.\nIn tota… [+2940 chars]\n----------------\n#------------------------------------------\n# 7\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Plos.org'}\n----------------\n----------------\nauthor\nOluseyi Ayinde, Jonathan D. C. Ross, Louise Jackson\n----------------\n----------------\ntitle\nEconomic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study\n----------------\n----------------\ndescription\nObjective To provide a summary of the economic and methodological evidence on capturing antimicrobial resistance (AMR) associated costs for curable sexually transmitted infections (STIs). To explore approaches for incorporating the cost of AMR within an econo…\n----------------\n----------------\nurl\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292273\n----------------\n----------------\nurlToImage\nhttps://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0292273.g004&size=inline\n----------------\n----------------\npublishedAt\n2023-10-19T14:00:00Z\n----------------\n----------------\ncontent\nCitation: Ayinde O, Ross JDC, Jackson L (2023) Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study. PLoS ONE 18(10):\n e02… [+35356 chars]\n----------------\n#------------------------------------------\n# 8\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Answersingenesis.org'}\n----------------\n----------------\nauthor\nPatricia Engler\n----------------\n----------------\ntitle\nThe Unknown Harvest: Organ Donation and the Definition of Death\n----------------\n----------------\ndescription\nWith life-and-death issues at stake, Christians must be aware of current medical practices to draw biblical boundaries.\n----------------\n----------------\nurl\nhttps://answersingenesis.org/human-body/organ-donation-and-definition-of-death/\n----------------\n----------------\nurlToImage\nhttps://assets.answersingenesis.org/img/cms/content/contentnode/og_image/unsplash-human-model.jpg\n----------------\n----------------\npublishedAt\n2023-10-06T10:00:00Z\n----------------\n----------------\ncontent\nOn questions of organ donation ethics and the definition of death, the stakes could hardly be higher. Thousands of lives hang in the balance amid a firestorm of controversy fueled by myriad questions… [+25304 chars]\n----------------\n#------------------------------------------\n# 9\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'PRNewswire'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nCAO Group, Inc. Starts A Program to Bring Patients to Dental Practice at No Cost!\n----------------\n----------------\ndescription\nSALT LAKE CITY, Oct. 2, 2023 /PRNewswire/ -- CAO Group Inc. (CAO) is stirring the pot by launching a new program to bring patients to dental practices at no cost to the practice. CAO begins a new campaign in the U.S. aimed directly at consumers involving Shee…\n----------------\n----------------\nurl\nhttps://www.prnewswire.com/news-releases/cao-group-inc-starts-a-program-to-bring-patients-to-dental-practice-at-no-cost-301943972.html\n----------------\n----------------\nurlToImage\nhttps://i.ytimg.com/vi/mQA73wlzLaY/hqdefault.jpg\n----------------\n----------------\npublishedAt\n2023-10-02T12:47:00Z\n----------------\n----------------\ncontent\nSALT LAKE CITY, Oct. 2, 2023 /PRNewswire/ -- CAO Group Inc. (CAO) is stirring the pot by launching a new program to bring patients to dental practices at no cost to the practice.\nCAO begins a new ca… [+2664 chars]\n----------------\n#------------------------------------------\n# 10\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Wealthofgeeks.com'}\n----------------\n----------------\nauthor\nRebecca Holcomb\n----------------\n----------------\ntitle\nMary Lou Retton’s Family Says She Is ‘Fighting for Her Life’ Due to Pneumonia\n----------------\n----------------\ndescription\nOlympic gymnastics star, Mary Lou Retton, is currently “fighting for her life” at just 55 years old against a rare form of pneumonia. According to ... Read More\n----------------\n----------------\nurl\nhttps://wealthofgeeks.com/mary-lou-rettons-pneumonia/\n----------------\n----------------\nurlToImage\nhttps://wealthofgeeks.com/wp-content/uploads/2023/10/mary-lou-retton.jpg\n----------------\n----------------\npublishedAt\n2023-10-12T14:45:14Z\n----------------\n----------------\ncontent\nOlympic gymnastics star, Mary Lou Retton, is currently “fighting for her life” at just 55 years old against a rare form of pneumonia.\nAccording to her daughter, McKenna Kelley, who created a Spotfun… [+2119 chars]\n----------------\n#------------------------------------------\n# 11\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Juancole.com'}\n----------------\n----------------\nauthor\nF. Douglas Stephenson\n----------------\n----------------\ntitle\nHow to Enroll Intelligently in Medicare – A Consumers Guide 2024\n----------------\n----------------\ndescription\nGainesville, FL (Special to Informed Comment)- Medicare open enrollment season begins October 15th, running through Dec.7, 2023. And very soon, everyone will be bombarded with new smarmy health insurance Medicare Advantage ads featuring healthy and happy-look…\n----------------\n----------------\nurl\nhttps://www.juancole.com/2023/10/intelligently-medicare-consumers.html\n----------------\n----------------\nurlToImage\nhttps://media.juancole.com/images/2023/10/doctor-6318045_640.png\n----------------\n----------------\npublishedAt\n2023-10-15T04:04:34Z\n----------------\n----------------\ncontent\nGainesville, FL (Special to Informed Comment)- Medicare open enrollment season begins October 15th, running through Dec.7, 2023. And very soon, everyone will be bombarded with new smarmy health insur… [+12485 chars]\n----------------\n#------------------------------------------\n# 12\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'PRNewswire'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nAmerican Council of Cannabis Medicine and Insurance Industry Leaders Prepare for New Era. First Open Enrollment Period to Prominently Include Medical Cannabis\n----------------\n----------------\ndescription\nWASHINGTON, Oct. 5, 2023 /PRNewswire/ -- The American Council of Cannabis Medicine (ACCM) announces major insurance industry and member-based group participation, to kick off open enrollment. After years of work, ACCM's Next Frontier platform, program, and in…\n----------------\n----------------\nurl\nhttps://www.prnewswire.com/news-releases/american-council-of-cannabis-medicine-and-insurance-industry-leaders-prepare-for-new-era-first-open-enrollment-period-to-prominently-include-medical-cannabis-301948483.html\n----------------\n----------------\nurlToImage\nhttps://mma.prnewswire.com/media/2239665/accm_Logo.jpg?p=facebook\n----------------\n----------------\npublishedAt\n2023-10-05T13:44:00Z\n----------------\n----------------\ncontent\nWASHINGTON, Oct. 5, 2023 /PRNewswire/ -- The American Council of Cannabis Medicine (ACCM) announces major insurance industry and member-based group participation, to kick off open enrollment. \nAfter… [+3959 chars]\n----------------\n#------------------------------------------\n# 13\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Wonkette.com'}\n----------------\n----------------\nauthor\nStephen Robinson\n----------------\n----------------\ntitle\nCA Gov Gavin Newsom Risks Political Career Apparently, Signs Couple Good Bills Into Law\n----------------\n----------------\ndescription\nNew ‘Ebony Alert’ will help save lives.\n----------------\n----------------\nurl\nhttps://www.wonkette.com/p/ca-gov-gavin-newsom-risks-political\n----------------\n----------------\nurlToImage\nhttps://substackcdn.com/image/fetch/w_1200,h_600,c_fill,f_jpg,q_auto:good,fl_progressive:steep,g_auto/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F76247f69-b61c-49f2-a275-60592d5c425d_1792x828.png\n----------------\n----------------\npublishedAt\n2023-10-11T18:15:13Z\n----------------\n----------------\ncontent\nCalifornia Gov. Gavin Newsom has done some crappy stuff recently, but lets start with a couple of things that are actually positive. Its been a tough week.\nLast night, Newsom signed a bill streamlin… [+6029 chars]\n----------------\n#------------------------------------------\n# 14\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'The Boston Globe'}\n----------------\n----------------\nauthor\nScot Lehigh\n----------------\n----------------\ntitle\nOn the presidential trail with N.H. voters\n----------------\n----------------\ndescription\nIn a state where residents once loved to talk presidential politics, it’s hard to get a full name in voter interviews because of fears of retaliation about their views on Donald Trump.\n----------------\n----------------\nurl\nhttps://www.bostonglobe.com/2023/10/12/opinion/2024-presidential-race-new-hampshire-voters-donald-trump/\n----------------\n----------------\nurlToImage\nhttps://bostonglobe-prod.cdn.arcpublishing.com/resizer/8ja-wkhyAIilt_cvri6s2e_RgmE=/506x0/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/3J55I7WI7CB2BXWYZ6H3RN6EVA.jpg\n----------------\n----------------\npublishedAt\n2023-10-12T17:58:12Z\n----------------\n----------------\ncontent\nIf the GOP nominates Trump again, the Democrats win, said former New Hampshire House speaker Doug Scamman, who with his wife, Stella, also a former representative, had come to Exeter to check out can… [+4279 chars]\n----------------\n#------------------------------------------\n# 15\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nG MEDPAR : SECURITIES PURCHASE AGREEMENT - Form 6-K\n----------------\n----------------\ndescription\n(marketscreener.com) List of Subsidiaries:\n \n \n G Medical Innovations Holdings Ltd., a Cayman Islands exempted company, and its subsidiaries: G Medical Innovations Ltd., an Israeli corporation, G Medical Innovations USA Inc., a Delaware corporation, G Medical…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/G-MEDPAR-124171421/news/G-MEDPAR-SECURITIES-PURCHASE-AGREEMENT-Form-6-K-45032420/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdblanc.png\n----------------\n----------------\npublishedAt\n2023-10-10T20:05:05Z\n----------------\n----------------\ncontent\nSECURITIES PURCHASE AGREEMENT\nThis Securities Purchase Agreement (this \"Agreement\n\") is dated as of September 29, 2023, between G Medical Innovations Holdings Ltd., a Cayman Islands exempted compan… [+107791 chars]\n----------------\n#------------------------------------------\n# 16\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Zacjohnson.com'}\n----------------\n----------------\nauthor\nZac Johnson\n----------------\n----------------\ntitle\nDecoding Income: $38 an Hour’s Annual Equivalent\n----------------\n----------------\ndescription\nHave you ever wondered how much $38 an hour amounts to in a year? We’ve got you covered. Whether you’re curious about calculating your annual salary from an hourly wage or simply want to understand the financial implications of earning $38 an hour, this artic…\n----------------\n----------------\nurl\nhttps://zacjohnson.com/38-an-hour-is-how-much-a-year/\n----------------\n----------------\nurlToImage\nhttps://zacjohnson.com/wp-content/uploads/2023/10/Calculating-Annual-Salary-1.jpg\n----------------\n----------------\npublishedAt\n2023-10-18T17:17:45Z\n----------------\n----------------\ncontent\nHave you ever wondered how much $38 an hour amounts to in a year? We’ve got you covered. Whether you’re curious about calculating your annual salary from an hourly wage or simply want to understand t… [+17003 chars]\n----------------\n#------------------------------------------\n# 17\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Naturalnews.com'}\n----------------\n----------------\nauthor\nMike Adams\n----------------\n----------------\ntitle\nCHAIN REACTION: 22 DEVASTATING things that will happen if Israel launches full assault against Gaza\n----------------\n----------------\ndescription\nIsrael’s full-scale ground assault against Gaza has reportedly been delayed so that the U.S. military can position additional anti-missile defense systems around the country, according to the WSJ. This is confirmation that the U.S. anticipates a strong kineti…\n----------------\n----------------\nurl\nhttps://www.naturalnews.com/2023-10-25-chain-reaction-22-devastating-things-that-will-happen-israel-gaza.html\n----------------\n----------------\nurlToImage\nhttps://www.naturalnews.com/wp-content/uploads/sites/91/2023/10/Gaza-Palestine-Damage-Israeli-Airstrikes.jpg\n----------------\n----------------\npublishedAt\n2023-10-25T06:00:00Z\n----------------\n----------------\ncontent\nIsrael's full-scale ground assault against Gaza has reportedly been delayed so that the U.S. military can position additional anti-missile defense systems around the country, according to the WSJ. Th… [+13380 chars]\n----------------\n#------------------------------------------\n# 18\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nFictiv Launches Major USA 3D Printing Service Expansion\n----------------\n----------------\ndescription\n(marketscreener.com) \n\nNewly expanded capabilities, advanced configuration options, and a significant pricing reduction delivers full-suite additive manufacturing capabilities for prototyping & production in the USA.\nSAN FRANCISCO, Oct. 17, 2023 /PRNewswire/ …\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/JABIL-INC-13153/news/Fictiv-Launches-Major-USA-3D-Printing-Service-Expansion-45081233/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdnoir.png\n----------------\n----------------\npublishedAt\n2023-10-17T13:01:14Z\n----------------\n----------------\ncontent\nNewly expanded capabilities, advanced configuration options, and a significant pricing reduction delivers full-suite additive manufacturing capabilities for prototyping &amp; production in the USA.\n… [+3829 chars]\n----------------\n#------------------------------------------\n# 19\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'The Week Magazine'}\n----------------\n----------------\nauthor\ntheweekonlineeditors@futurenet.com (Harold Maass, The Week US)\n----------------\n----------------\ntitle\n10 things you need to know today: October 13, 2023\n----------------\n----------------\ndescription\nIsrael orders civilians to leave northern Gaza ahead of ground assault, Scalise withdraws his bid to become House speaker, and more\n----------------\n----------------\nurl\nhttps://theweek.com/digest/round-up/10-things-you-need-to-know-today-october-13-2023\n----------------\n----------------\nurlToImage\nhttps://cdn.mos.cms.futurecdn.net/sUoPLGPuCpAb4pEc38SbhZ-1200-80.jpg\n----------------\n----------------\npublishedAt\n2023-10-13T11:23:33Z\n----------------\n----------------\ncontent\nA free daily digest of the biggest news stories of the day - and the best features from our website\nThank you for signing up to TheWeek. You will receive a verification email shortly.\nThere was a p… [+8650 chars]\n----------------\n#------------------------------------------\n# 20\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nMedunik USA\n----------------\n----------------\ntitle\nPheburane® (sodium phenylbutyrate) coverage to reach ~80% of commercially insured US patients by January 1st, 2024\n----------------\n----------------\ndescription\nPRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group, an international company selected in the Government of Canada's first Global Hypergrowth Project) is pleased to announce that as of January 1st, 2024, Ph…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/26/2767387/0/en/Pheburane-sodium-phenylbutyrate-coverage-to-reach-80-of-commercially-insured-US-patients-by-January-1st-2024.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/e16eb8f7-1f47-406e-8115-f0f06c568b58\n----------------\n----------------\npublishedAt\n2023-10-26T11:30:00Z\n----------------\n----------------\ncontent\nPRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group, an international company selected in the Government of Canada's first Global Hypergrowth Proj… [+10981 chars]\n----------------\n#------------------------------------------\n# 21\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nSkyQuest Technology Consulting Pvt. Ltd.\n----------------\n----------------\ntitle\nBench Top Dental Autoclaves Market Set to Soar Past USD 196 Million by 2030\n----------------\n----------------\ndescription\nThe global Bench Top Dental Autoclaves market size is expected to reach USD 196 million by 2030 and exhibit a CAGR of 5.4% in the forecast period (2023−2030) according to Skyquest's latest research report. The growing dental industry demand, increasing focus …\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/19/2763432/0/en/Bench-Top-Dental-Autoclaves-Market-Set-to-Soar-Past-USD-196-Million-by-2030.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/c673c6fa-f0e7-47bf-8490-fe528c593820\n----------------\n----------------\npublishedAt\n2023-10-19T15:17:00Z\n----------------\n----------------\ncontent\nWestford USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest's latest global research of the Bench Top Dental Autoclaves market\n, increasing demand for portable and lightweight autoclaves, … [+5454 chars]\n----------------\n#------------------------------------------\n# 22\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Cdc.gov'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nRacial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA\n----------------\n----------------\ndescription\nEquity of Treatment during Mpox, New York, USA\n----------------\n----------------\nurl\nhttps://wwwnc.cdc.gov/eid/article/29/11/23-0814_article\n----------------\n----------------\nurlToImage\nhttps://wwwnc.cdc.gov/eid/images/og-eid-logo-2.jpg\n----------------\n----------------\npublishedAt\n2023-10-05T04:00:00Z\n----------------\n----------------\ncontent\nDisclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.In May 2022, mpox cases we… [+10234 chars]\n----------------\n#------------------------------------------\n# 23\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Breakingmuscle.com'}\n----------------\n----------------\nauthor\nMegan Toomey MS, RD, CSR, LDN\n----------------\n----------------\ntitle\nBest Tasting Protein Powder (2023): Flavors You’ll Crave and Quality You Can Trust\n----------------\n----------------\ndescription\nAs a registered dietitian, I am asked almost every day for recommendations on the best type of protein supplement. And while I’m sure to only recommend proteins whose quality and formulation I can stand behind, there’s another feature that’s also pretty impor…\n----------------\n----------------\nurl\nhttps://breakingmuscle.com/best-tasting-protein-powder/\n----------------\n----------------\nurlToImage\nhttps://breakingmuscle.com/wp-content/uploads/2023/10/BM_Featured_BestTastingProteinPowder.jpg\n----------------\n----------------\npublishedAt\n2023-10-12T20:40:13Z\n----------------\n----------------\ncontent\nWe receive free products and receive commissions through our links. See disclosures page.\nAs a registered dietitian, I am asked almost every day for recommendations on the best type of protein suppl… [+33926 chars]\n----------------\n#------------------------------------------\n# 24\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Lesswrong.com'}\n----------------\n----------------\nauthor\naggliu\n----------------\n----------------\ntitle\nHow to Eradicate Global Extreme Poverty [RA video with fundraiser!]\n----------------\n----------------\ndescription\nPublished on October 18, 2023 3:51 PM GMTCross-posted from the EA Forum\nIn this video, we outline a plan to eradicate global extreme poverty using cash transfers. The approach is based on GiveDirectly's internal research and documentation about the topic. Al…\n----------------\n----------------\nurl\nhttps://www.lesswrong.com/posts/Lw5bmncMRJw5kDwqN/how-to-eradicate-global-extreme-poverty-ra-video-with\n----------------\n----------------\nurlToImage\nhttps://res.cloudinary.com/lesswrong-2-0/image/upload/v1654295382/new_mississippi_river_fjdmww.jpg\n----------------\n----------------\npublishedAt\n2023-10-18T15:51:22Z\n----------------\n----------------\ncontent\nCross-posted from the EA Forum\nIn this video, we outline a plan to eradicate global extreme poverty using cash transfers. The approach is based on GiveDirectly's internal research and documentation … [+18139 chars]\n----------------\n#------------------------------------------\n# 25\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nLiveCare Inc.\n----------------\n----------------\ntitle\nLiveCare's Member Acquisition Surges With In-House Program\n----------------\n----------------\ndescription\nVenice, FL, USA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- LiveCare, Inc. (OTC:LVCE), a pioneering force in the telehealth sector dedicated to supporting type II diabetes patients often overlooked, proudly announces the success of its innovative in-house patient acqu…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/20/2764058/0/en/LiveCare-s-Member-Acquisition-Surges-With-In-House-Program.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/65634c5e-73bb-4c49-995d-d399ede095ab\n----------------\n----------------\npublishedAt\n2023-10-20T13:30:00Z\n----------------\n----------------\ncontent\nVenice, FL, USA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- LiveCare, Inc. (OTC:LVCE), a pioneering force in the telehealth sector dedicated to supporting type II diabetes patients often overlooked, proudly a… [+3441 chars]\n----------------\n#------------------------------------------\n# 26\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nSkyQuest Technology Consulting Pvt. Ltd.\n----------------\n----------------\ntitle\nPneumatic Cylinder Market Set to Soar Past USD 2057.75 Million by 2030 | Skyquest Technology\n----------------\n----------------\ndescription\nThe global Pneumatic Cylinder market size is expected to reach USD 2057.75 million by 2030 and exhibit a CAGR of 5.3% in the forecast period (2023−2030), according to Skyquest's latest research report. The growing industrial automation and robotics, increasin…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/23/2764543/0/en/Pneumatic-Cylinder-Market-Set-to-Soar-Past-USD-2057-75-Million-by-2030-Skyquest-Technology.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/c673c6fa-f0e7-47bf-8490-fe528c593820\n----------------\n----------------\npublishedAt\n2023-10-23T10:31:00Z\n----------------\n----------------\ncontent\nWestford, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest's latest global research of the Pneumatic Cylinder market\n, increasing adoption of smart and connected pneumatic cylinders, int… [+5543 chars]\n----------------\n#------------------------------------------\n# 27\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nSNS Insider pvt ltd\n----------------\n----------------\ntitle\nDigital Isolator Market to Hit USD 882.90 Million by 2030 | Research by SNS Insider\n----------------\n----------------\ndescription\nDigital Isolator Market is calculated 1.80 Billion by 2022 - on Account of Digital Transformation and Industry 4.0 Coupled with Medical Technology Advancements Digital Isolator Market is calculated 1.80 Billion by 2022 - on Account of Digital Transformation a…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/17/2761630/0/en/Digital-Isolator-Market-to-Hit-USD-882-90-Million-by-2030-Research-by-SNS-Insider.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/cb2adc75-7bac-484e-a705-cb2addc4a99e\n----------------\n----------------\npublishedAt\n2023-10-17T13:28:00Z\n----------------\n----------------\ncontent\nPune, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Based on SNS Insiders research, the digital isolator market is poised for substantial growth, driven by factors such as safety regulations, miniaturization tre… [+12601 chars]\n----------------\n#------------------------------------------\n# 28\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nFuture Market Insights Global and Consulting Pvt. Ltd.\n----------------\n----------------\ntitle\nRapid Growth in Ultrafiltration Membranes Market to Reach US$ 10.7 billion Expected by 2033, Driven by Expanding Applications in Water Treatment and Beyond | Future Market Insights, Inc.\n----------------\n----------------\ndescription\nThe USA ultrafiltration membranes market is set to reach US$ 1.9 billion with a 10.9% historical CAGR, driven by water quality concerns and stringent regulations. The US leads in water treatment infrastructure and advanced separation technology adoption. The …\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/27/2768423/0/en/Rapid-Growth-in-Ultrafiltration-Membranes-Market-to-Reach-US-10-7-billion-Expected-by-2033-Driven-by-Expanding-Applications-in-Water-Treatment-and-Beyond-Future-Market-Insights-Inc.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/915d2f9c-7dc6-40c7-995c-2ba168208baa\n----------------\n----------------\npublishedAt\n2023-10-27T13:00:00Z\n----------------\n----------------\ncontent\nNEWARK, Del, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The global ultrafiltration membranes market is anticipated to be US$ 10.7 billion by 2033. It is estimated to record a steady CAGR of 8.0% in the review… [+9851 chars]\n----------------\n#------------------------------------------\n# 29\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAllied Market Research\n----------------\n----------------\ntitle\nSpecialty PACS Market Is Projected to Reach an Estimate of $4,485.96 Million By 2030, Claims Allied Market Research\n----------------\n----------------\ndescription\nThe global specialty PACS market growth is driven by the rise in investments in medical imaging, increasing utilization of imaging equipment, and the rise in the geriatric population. The global specialty PACS market growth is driven by the rise in investment…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/26/2767053/0/en/Specialty-PACS-Market-Is-Projected-to-Reach-an-Estimate-of-4-485-96-Million-By-2030-Claims-Allied-Market-Research.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/9c430095-89f7-48b4-b8f0-e1f4ed1a5660\n----------------\n----------------\npublishedAt\n2023-10-26T00:30:00Z\n----------------\n----------------\ncontent\nWilmington, Delaware, Oct. 25, 2023 (GLOBE NEWSWIRE) -- According to the report released by Allied Market Research, titled, Specialty PACS Market by Type (Women's Health PACS, Orthopedics PACS, Radio… [+8245 chars]\n----------------\n#------------------------------------------\n# 30\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Plos.org'}\n----------------\n----------------\nauthor\nMaddalena Ferranna, Daniel Cadarette, Simiao Chen, Parastou Ghazi, Faith Ross, Leo Zucker, David E. Bloom\n----------------\n----------------\ntitle\nThe macroeconomic burden of noncommunicable diseases and mental health conditions in South America\n----------------\n----------------\ndescription\nNoncommunicable diseases and mental health conditions (referred to collectively as NMHs) are the greatest cause of preventable death, illness, and disability in South America and negatively affect countries’ economic performance through their detrimental impa…\n----------------\n----------------\nurl\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0293144\n----------------\n----------------\nurlToImage\nhttps://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0293144.g003&size=inline\n----------------\n----------------\npublishedAt\n2023-10-20T14:00:00Z\n----------------\n----------------\ncontent\nAbstract\nNoncommunicable diseases and mental health conditions (referred to collectively as NMHs) are the greatest cause of preventable death, illness, and disability in South America and negatively… [+52530 chars]\n----------------\n#------------------------------------------\n# 31\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nResearch and Markets\n----------------\n----------------\ntitle\nGlobal Mobile Imaging Services Market Research Report 2023: Market to Reach $2.7 Billion by 2030 - Artificial Intelligence at the Forefront in New Portable Ultrasound Systems\n----------------\n----------------\ndescription\nDublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The \"Mobile Imaging Services - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.Global Mobile Imaging Services Market to Reach $2.7 Billion by 2030The global market for Mobi…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/17/2761262/28124/en/Global-Mobile-Imaging-Services-Market-Research-Report-2023-Market-to-Reach-2-7-Billion-by-2030-Artificial-Intelligence-at-the-Forefront-in-New-Portable-Ultrasound-Systems.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\n----------------\n----------------\npublishedAt\n2023-10-17T08:58:00Z\n----------------\n----------------\ncontent\nDublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The \"Mobile Imaging Services - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.\nGlobal Mobile Imaging Services … [+6049 chars]\n----------------\n#------------------------------------------\n# 32\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'The Times of Israel'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nBlue Vibe CBD Gummies Reviews (Urgent Consumer Reports) Side Effects SCAM OR LEGIT Ingredients? - Sponsored Content\n----------------\n----------------\ndescription\nTop 4 CBD Consumer Reports Reviews - Blue Vibe CBD Gummies, Wellness Peak CBD Gummies, Gentle Wave CBD Gummies, Apollo CBD Gummies\n----------------\n----------------\nurl\nhttps://www.timesofisrael.com/spotlight/blue-vibe-cbd-gummies-reviews/\n----------------\n----------------\nurlToImage\nhttps://static.timesofisrael.com/www/images/toi_icon_fb_1200.png\n----------------\n----------------\npublishedAt\n2023-10-10T00:42:32Z\n----------------\n----------------\ncontent\nCBD gummies are revolutionary products that have gained brisk popularity because of their potential to treat a variety of ailments. Blue Vibe CBD Gummies benefit a person with a good mood, good sleep… [+22630 chars]\n----------------\n#------------------------------------------\n# 33\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'The Times of Israel'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nBlue Vibe CBD Gummies Reviews (Urgent Consumer Reports) Side Effects SCAM OR LEGIT Ingredients? - Sponsored Content\n----------------\n----------------\ndescription\nTop 4 CBD Consumer Reports Reviews - Blue Vibe CBD Gummies, Wellness Peak CBD Gummies, Gentle Wave CBD Gummies, Apollo CBD Gummies\n----------------\n----------------\nurl\nhttps://www.timesofisrael.com/spotlight/blue-vibe-cbd-gummies-reviews-urgent-consumer-reports-side-effects-scam-or-legit-ingredients/\n----------------\n----------------\nurlToImage\nhttps://static.timesofisrael.com/www/images/toi_icon_fb_1200.png\n----------------\n----------------\npublishedAt\n2023-10-10T00:42:32Z\n----------------\n----------------\ncontent\nCBD gummies are revolutionary products that have gained brisk popularity because of their potential to treat a variety of ailments. Blue Vibe CBD Gummies benefit a person with a good mood, good sleep… [+22630 chars]\n----------------\n#------------------------------------------\n# 34\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Plos.org'}\n----------------\n----------------\nauthor\nChristopher L. Bennett, Allan S. Detsky, Carson E. Clay, Janice A. Espinola, Julie Parsonnet, Carlos A. Camargo\n----------------\n----------------\ntitle\nComparison of US emergency departments by HIV priority jurisdiction designation: A case for geographically targeted screening in teaching hospitals\n----------------\n----------------\ndescription\nThe Ending the HIV Epidemic (EHE) Initiative targets a subset of United States (US) priority jurisdictions hardest hit by HIV. It remains unclear which emergency departments (EDs) are the most appropriate targets for EHE-related efforts. To explore this, we u…\n----------------\n----------------\nurl\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292869\n----------------\n----------------\nurlToImage\nhttps://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0292869.g001&size=inline\n----------------\n----------------\npublishedAt\n2023-10-18T14:00:00Z\n----------------\n----------------\ncontent\nAbstract\nThe Ending the HIV Epidemic (EHE) Initiative targets a subset of United States (US) priority jurisdictions hardest hit by HIV. It remains unclear which emergency departments (EDs) are the m… [+36302 chars]\n----------------\n#------------------------------------------\n# 35\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nGlobeNewswire\n----------------\n----------------\ntitle\nFemasys Inc. MDSAP Surveillance Audit Successfully Completed\n----------------\n----------------\ndescription\n(marketscreener.com) – Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed to bringing innovative solutions to women around the world – ATLANTA, Oct. 03, 2023 -- Fem…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/FEMASYS-INC-123820666/news/Femasys-Inc-MDSAP-Surveillance-Audit-Successfully-Completed-44972647/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdnoir.png\n----------------\n----------------\npublishedAt\n2023-10-03T12:32:02Z\n----------------\n----------------\ncontent\nFemasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA \n Femasys is committed to bringing innovative solutions to women around the w… [+5381 chars]\n----------------\n#------------------------------------------\n# 36\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nCognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA\n----------------\n----------------\ndescription\n(marketscreener.com) Cognetivity Neurosciences Ltd.   , a leading artificial intelligence healthcare technology company is delighted to announce a collaboration with UC Health, one of the leading healthcare systems in the United States, to improve early detec…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/COGNETIVITY-NEUROSCIENCES-42413949/news/Cognetivity-Neurosciences-and-UC-Health-Partner-to-Improve-Early-Detection-of-Cognitive-Impairment-i-45040405/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdblanc.png\n----------------\n----------------\npublishedAt\n2023-10-11T13:05:02Z\n----------------\n----------------\ncontent\nVancouver, British Columbia--(Newsfile Corp. - October 11, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) (\"the Company\" or \"Cognetivity\"), a leading artificial intell… [+6403 chars]\n----------------\n#------------------------------------------\n# 37\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Thehillstimes.in'}\n----------------\n----------------\nauthor\nThe Hills Times\n----------------\n----------------\ntitle\n80 % Indians With Mental Illness Don’t Seek Treatment: Health Experts\n----------------\n----------------\ndescription\nNEW DELHI, Oct 9: 80 per cent of Indians with mental health issues do not seek treatment, doctors have said and cited lack of awareness, neglect and stigma as the reasons for this. They stressed that awareness about physical as well as mental health should be…\n----------------\n----------------\nurl\nhttps://thehillstimes.in/national/80-indians-with-mental-illness-dont-seek-treatment-health-experts\n----------------\n----------------\nurlToImage\nhttps://thehillstimes.in/wp-content/uploads/2023/10/295.jpg\n----------------\n----------------\npublishedAt\n2023-10-11T00:10:46Z\n----------------\n----------------\ncontent\nNEW DELHI, Oct 9: 80 per cent of Indians with mental health issues do not seek treatment, doctors have said and cited lack of awareness, neglect and stigma as the reasons for this.\nThey stressed tha… [+3880 chars]\n----------------\n#------------------------------------------\n# 38\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Dansdeals.com'}\n----------------\n----------------\nauthor\nDan\n----------------\n----------------\ntitle\nChase Freedom’s Excellent Q4 5x Bonus Categories Are Live\n----------------\n----------------\ndescription\nChase Freedom Flex and Freedom are excellent no annual fee cards thanks to their quarterly 5% categories. While the rewards are marketed as 5% cash back, you’ll actually get 5 Ultimate Rewards points per dollar spent which can be worth much more than 5% cash.…\n----------------\n----------------\nurl\nhttps://www.dansdeals.com/credit-cards/chase-freedoms-excellent-q4-5x-bonus-categories-live-2/\n----------------\n----------------\nurlToImage\nhttps://i.dansdeals.com/wp-content/uploads/2019/01/25124023/freedom_flex_card_alt.png\n----------------\n----------------\npublishedAt\n2023-10-02T15:49:07Z\n----------------\n----------------\ncontent\nChase Freedom Flex and Freedom are excellent no annual fee cards thanks to their quarterly 5% categories. While the rewards are marketed as 5% cash back, youll actually get 5 Ultimate Rewards points … [+3599 chars]\n----------------\n#------------------------------------------\n# 39\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'New York Post'}\n----------------\n----------------\nauthor\nRich Calder\n----------------\n----------------\ntitle\nHochul paying NYers $25 for tobacco survey, but no questions on pot ban\n----------------\n----------------\ndescription\nThe Hochul administration is shelling out at least $150,000 in taxpayer money to survey New Yorkers about banning the sale of tobacco products -- but bizarrely isn’t asking them about pot.\n----------------\n----------------\nurl\nhttps://nypost.com/2023/10/07/hochul-paying-nyers-25-to-test-market-tobacco-sale-ban/\n----------------\n----------------\nurlToImage\nhttps://nypost.com/wp-content/uploads/sites/2/2023/10/NYPICHPDPICT000057948535.jpg?quality=75&strip=all&w=1024\n----------------\n----------------\npublishedAt\n2023-10-07T16:48:16Z\n----------------\n----------------\ncontent\nNew York tax dollars are going up in smoke.\nThe Hochul administration is shelling out at least $150,000 in taxpayer money to survey New Yorkers about banning the sale of tobacco products — but bizar… [+4464 chars]\n----------------\n#------------------------------------------\n# 40\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Plos.org'}\n----------------\n----------------\nauthor\nColin D. Middleton, Kim Boynton, David Lewis, Andrew M. Oster\n----------------\n----------------\ntitle\nThe value of utility payment history in predicting first-time homelessness\n----------------\n----------------\ndescription\nHomelessness is a costly and traumatic condition that affects hundreds of thousands of people each year in the U.S. alone. Most homeless programs focus on assisting people experiencing homelessness, but research has shown that predicting and preventing homele…\n----------------\n----------------\nurl\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292305\n----------------\n----------------\nurlToImage\nhttps://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0292305.g004&size=inline\n----------------\n----------------\npublishedAt\n2023-10-09T14:00:00Z\n----------------\n----------------\ncontent\nAbstract\nHomelessness is a costly and traumatic condition that affects hundreds of thousands of people each year in the U.S. alone. Most homeless programs focus on assisting people experiencing home… [+57492 chars]\n----------------\n#------------------------------------------\n# 41\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'MediaNama.com'}\n----------------\n----------------\nauthor\nGuest Author\n----------------\n----------------\ntitle\nTowards Greater Cloud Adoption in CII sectors\n----------------\n----------------\ndescription\nCritical Information Infrastructure (CII) sectors are those designated by the Government of India as such, due to the key role they play in maintaining the upkeep of vital areas such as national security, economy, public health and more.\nThe post Towards Grea…\n----------------\n----------------\nurl\nhttps://www.medianama.com/2023/10/223-cloud-adoption-cii-sectors-india/\n----------------\n----------------\nurlToImage\nhttps://www.medianama.com/wp-content/uploads/2021/04/79-scaled.jpg\n----------------\n----------------\npublishedAt\n2023-10-27T10:33:13Z\n----------------\n----------------\ncontent\nBy Shachi Solanki\nIn 2013 when the Government of India came up with its Cloud policy, it wanted its entities to adopt it as their first option to deliver services to the public. However, the Cloud F… [+6945 chars]\n----------------\n#------------------------------------------\n# 42\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nVisible acceleration in clinical trial with already more than 60 patients; increase in funding of around EUR 0.4 million underscores innovative strength of silver coating technology\n----------------\n----------------\ndescription\n(marketscreener.com) General Standard/Regulated Market - All German Stock Exchanges -\n\n \n\n \n\nAbout aap Implantate AGaap Implantate AG is a globally active medical technology company headquartered in Berlin, Germany. The company develops, manufactures and mark…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/AAP-IMPLANTATE-AG-435617/news/Visible-acceleration-in-clinical-trial-with-already-more-than-60-patients-increase-in-funding-of-ar-45183753/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdnoir.png\n----------------\n----------------\npublishedAt\n2023-10-30T10:47:02Z\n----------------\n----------------\ncontent\nEQS-News: aap Implantate AG\n/ Key word(s): Study\nVisible acceleration in clinical trial with already more than 60 patients; increase in funding of around EUR 0.4 million underscores innovative stre… [+5875 chars]\n----------------\n#------------------------------------------\n# 43\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nResearch and Markets\n----------------\n----------------\ntitle\nGlobal Inferior Vena Cava (IVC) Filters Research Analysis Report 2023: Market to Reach $1.5 Billion by 2030 - Rising Incidence of Deep Vein Thrombosis and Pulmonary Embolisms Spurs Demand\n----------------\n----------------\ndescription\nDublin, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The \"Inferior Vena Cava (IVC) Filters - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.Global Inferior Vena Cava (IVC) Filters Market to Reach $1.5 Billion by 2030The glob…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/27/2768479/28124/en/Global-Inferior-Vena-Cava-IVC-Filters-Research-Analysis-Report-2023-Market-to-Reach-1-5-Billion-by-2030-Rising-Incidence-of-Deep-Vein-Thrombosis-and-Pulmonary-Embolisms-Spurs-Deman.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\n----------------\n----------------\npublishedAt\n2023-10-27T13:48:00Z\n----------------\n----------------\ncontent\nDublin, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The \"Inferior Vena Cava (IVC) Filters - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.\nGlobal Inferior Vena C… [+5850 chars]\n----------------\n#------------------------------------------\n# 44\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Kevinmd.com'}\n----------------\n----------------\nauthor\nCurtis G. Graham, MD\n----------------\n----------------\ntitle\nPrivate medical practice: thriving with business knowledge\n----------------\n----------------\ndescription\nAre you happy and satisfied with your private medical practice today? Over 65 percent of physicians admit they aren’t. Such a high percentage is indicative of serious problems within the medical profession that aren’t being resolved. These issues are increasi…\n----------------\n----------------\nurl\nhttps://www.kevinmd.com/2023/10/private-medical-practice-thriving-with-business-knowledge.html\n----------------\n----------------\nurlToImage\nhttps://www.kevinmd.com/wp-content/uploads/shutterstock_1926913298-1.jpg\n----------------\n----------------\npublishedAt\n2023-10-23T15:00:56Z\n----------------\n----------------\ncontent\nAre you happy and satisfied with your private medical practice today? Over 65 percent of physicians admit they aren’t. Such a high percentage is indicative of serious problems within the medical prof… [+5514 chars]\n----------------\n#------------------------------------------\n# 45\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Macdailynews.com'}\n----------------\n----------------\nauthor\nMacDailyNews\n----------------\n----------------\ntitle\nNew Apple research highlights the health benefits of pickleball and tennis\n----------------\n----------------\ndescription\nResearchers from the Apple Heart and Movement Study share new insights into one of the fastest-growing sports around the world: pickleball…\nThe post New Apple research highlights the health benefits of pickleball and tennis appeared first on MacDailyNews.\n----------------\n----------------\nurl\nhttps://macdailynews.com/2023/10/18/new-apple-research-highlights-the-health-benefits-of-pickleball-and-tennis/\n----------------\n----------------\nurlToImage\nhttps://149359564.v2.pressablecdn.com/wp-content/uploads/2023/10/231018_pickleball.png\n----------------\n----------------\npublishedAt\n2023-10-18T15:13:34Z\n----------------\n----------------\ncontent\nResearchers from the Apple Heart and Movement Study found trends in both pickleball and tennis workout data that highlight the potential health benefits of both activities.\nResearchers from the Appl… [+8992 chars]\n----------------\n#------------------------------------------\n# 46\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nNIOX : INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023\n----------------\n----------------\ndescription\n(marketscreener.com) \n INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023\n \n \n Oxford, UK - 26 September 2023: NIOX Group plc , a company engaged in the design, development, and commercialisation of medical devices for asthma diagnosis and management, toda…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/NIOX-GROUP-PLC-16012085/news/NIOX-INTERIM-RESULTS-FOR-THE-SIX-MONTHS-ENDED-30-JUNE-2023-45123057/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdblanc.png\n----------------\n----------------\npublishedAt\n2023-10-23T09:04:02Z\n----------------\n----------------\ncontent\nINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023\n Oxford, UK - 26 September 2023: NIOX Group plc (AIM: NIOX), a company engaged in the design, development, and commercialisation of medical devi… [+6507 chars]\n----------------\n#------------------------------------------\n# 47\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nNovartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer\n----------------\n----------------\ndescription\n(marketscreener.com) Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed October 2023.European Society for Medical Oncology – Magnitude of Clinical Benefit Scale Scoreca…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-Kisqali-NATALEE-analysis-reinforces-consistent-reduction-in-risk-of-recurrence-across-key-45112681/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdblanc.png\n----------------\n----------------\npublishedAt\n2023-10-20T10:01:01Z\n----------------\n----------------\ncontent\n&lt;ul&gt;&lt;li&gt;Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tu… [+21157 chars]\n----------------\n#------------------------------------------\n# 48\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'NDTV News'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nHow to Buy Trenbolone in the USA: Real Tren Steroid for sale\n----------------\n----------------\ndescription\nIts not always easy ordering online these days, especially when it comes to things like Trenbolone. Here, you can find all the details you need to buy genuine Trenbolone online safely, list of best Tren brands and their prices.\n----------------\n----------------\nurl\nhttps://www.ndtv.com/partner-content/health-supplements/how-to-buy-trenbolone-in-the-usa-real-tren-steroid-for-sale-4468206\n----------------\n----------------\nurlToImage\nhttps://c.ndtvimg.com/2023-10/d7vt178g_reckonsoft_625x300_10_October_23.png\n----------------\n----------------\npublishedAt\n2023-10-10T13:05:34Z\n----------------\n----------------\ncontent\nWith our easy-to-follow guide, you'll get clear and simple tips on how to choose and use this strong muscle-building substance. We'll also tell you how to buy it online without falling victim to all … [+24151 chars]\n----------------\n#------------------------------------------\n# 49\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'PR Newswire UK'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nWorld Stroke Day: World Stroke Organization calls for Action on Prevention as Global Stroke Mortality is Predicted to Rise by 50%\n----------------\n----------------\ndescription\nGENEVA, Oct. 27, 2023 /PRNewswire/ -- The World Stroke Organization (WSO) is calling on governments and healthcare systems to implement recommendations on stroke prevention set out in the new WSO-Lancet Neurology Commission report. The Commission report, base…\n----------------\n----------------\nurl\nhttps://www.prnewswire.co.uk/news-releases/world-stroke-day-world-stroke-organization-calls-for-action-on-prevention-as-global-stroke-mortality-is-predicted-to-rise-by-50-301969390.html\n----------------\n----------------\nurlToImage\nhttps://mma.prnewswire.com/media/2259018/hiking.jpg?p=facebook\n----------------\n----------------\npublishedAt\n2023-10-27T07:00:00Z\n----------------\n----------------\ncontent\nGENEVA, Oct. 27, 2023 /PRNewswire/ -- The World Stroke Organization (WSO) is calling on governments and healthcare systems to implement recommendations on stroke prevention set out in the new WSO-Lan… [+3928 chars]\n----------------\n#------------------------------------------\n# 50\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nBPH Energy : Cortical Dynamics Limited June 2023 Annual Report\n----------------\n----------------\ndescription\n(marketscreener.com) \n \n Cortical Dynamics Limited\n \n \n ACN 107 557 620\n \n \n Financial Report 30 June 2023\n \n \n \n \n \n \n \n \n Contents\n \n \n \n \n \n \n \n \n \n ...https://www.marketscreener.com/quote/stock/BPH-ENERGY-LIMITED-10353907/news/BPH-Energy-Cortical-Dynamics…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/BPH-ENERGY-LIMITED-10353907/news/BPH-Energy-Cortical-Dynamics-Limited-June-2023-Annual-Report-45190546/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdnoir.png\n----------------\n----------------\npublishedAt\n2023-10-30T22:37:04Z\n----------------\n----------------\ncontent\nCortical Dynamics Limited\nACN 107 557 620\nFinancial Report 30 June 2023\n&lt;table&gt;&lt;tr&gt;&lt;td&gt;\nContents\n&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;\nCortical Dynamics Limited\n&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;\nPag… [+25941 chars]\n----------------\n#------------------------------------------\n# 51\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nPersistence Market Research\n----------------\n----------------\ntitle\n3D Printing Metal Market Expected to Reach US$ 2.95 Billion by 2032, Fueled by Surging Demand in the Medical Industry: Persistence Market Research\n----------------\n----------------\ndescription\nRising demand across diverse industries makes the U.S. a leading global consumer of 3D printing metals, holding a dominant 49.3% market share Rising demand across diverse industries makes the U.S. a leading global consumer of 3D printing metals, holding a dom…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/27/2768252/0/en/3D-Printing-Metal-Market-Expected-to-Reach-US-2-95-Billion-by-2032-Fueled-by-Surging-Demand-in-the-Medical-Industry-Persistence-Market-Research.html\n----------------\n----------------\nurlToImage\nNone\n----------------\n----------------\npublishedAt\n2023-10-27T10:27:00Z\n----------------\n----------------\ncontent\nNew York, Oct. 27, 2023 (GLOBE NEWSWIRE) -- According to the latest market assessments by Persistence Market Research, the worldwide 3D printing metal market was worth $422.9 million in 2022, and it … [+16929 chars]\n----------------\n#------------------------------------------\n# 52\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'NDTV News'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nSteroids for sale in the USA: How to Buy Steroids Online\n----------------\n----------------\ndescription\nBuying steroids in the USA can be tricky. The key is to make sure you buy from a seller you can trust. This steroids buying guide will help you to identify reputable sellers, provide discount codes and share prices of major anabolic steroids brands.\n----------------\n----------------\nurl\nhttps://www.ndtv.com/partner-content/health-supplements/steroids-for-sale-in-the-usa-how-to-buy-steroids-online-4467925\n----------------\n----------------\nurlToImage\nhttps://c.ndtvimg.com/2023-10/asongdfo_reckonsoft_625x300_10_October_23.png\n----------------\n----------------\npublishedAt\n2023-10-10T11:59:18Z\n----------------\n----------------\ncontent\nWith so much fake news out there, getting the right advice is crucial. When getting into steroids, some are safe for everyone, and others are not. We're here to help you find which is which. By readi… [+35750 chars]\n----------------\n#------------------------------------------\n# 53\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Plos.org'}\n----------------\n----------------\nauthor\nDavid S. Henry, Richard G. Pellegrino\n----------------\n----------------\ntitle\nA case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial\n----------------\n----------------\ndescription\nBackground Phosphodiesterase-5 inhibitors (PDE5i) have been evaluated as a novel treatment for Alzheimer’s disease and related dementias (ADRD), but two recent cohort studies have offered opposing conclusions.   Methods We performed an unmatched case-control …\n----------------\n----------------\nurl\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292863\n----------------\n----------------\nurlToImage\nhttps://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0292863.g001&size=inline\n----------------\n----------------\npublishedAt\n2023-10-18T14:00:00Z\n----------------\n----------------\ncontent\nAbstract\nBackground\nPhosphodiesterase-5 inhibitors (PDE5i) have been evaluated as a novel treatment for Alzheimers disease and related dementias (ADRD), but two recent cohort studies have offered o… [+51119 chars]\n----------------\n#------------------------------------------\n# 54\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAcumen Research and Consulting\n----------------\n----------------\ntitle\nPerfusion Systems Market to Reach USD 1.9 Billion by 2032, Growing at 4.5% CAGR\n----------------\n----------------\ndescription\nAcumen Research and Consulting recently published report titled “Perfusion Systems Market 2023 - 2032” Acumen Research and Consulting recently published report titled “Perfusion Systems Market 2023 - 2032”\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/20/2764100/0/en/Perfusion-Systems-Market-to-Reach-USD-1-9-Billion-by-2032-Growing-at-4-5-CAGR.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d\n----------------\n----------------\npublishedAt\n2023-10-20T14:20:00Z\n----------------\n----------------\ncontent\nLOS ANGELES, Oct. 20, 2023 (GLOBE NEWSWIRE) -- The Global Perfusion Systems Market Size accounted for USD 1.3 Billion in 2022 and is projected to achieve a market size of USD 1.9 Billion by 2032 grow… [+9425 chars]\n----------------\n#------------------------------------------\n# 55\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Plos.org'}\n----------------\n----------------\nauthor\nComfort Ropafadzo Kanji, Bianza Tinotenda Mbavha, Collen Masimirembwa, Roslyn Stella Thelingwani\n----------------\n----------------\ntitle\nAnalytical validation of GenoPharm a clinical genotyping open array panel of 46 pharmacogenes inclusive of variants unique to people of African ancestry\n----------------\n----------------\ndescription\nPharmacogenomic testing may be used to improve treatment outcomes and reduce the frequency of adverse drug reactions (ADRs). Population specific, targeted pharmacogenetics (PGx) panel-based testing methods enable sensitive, accurate and economical implementat…\n----------------\n----------------\nurl\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292131\n----------------\n----------------\nurlToImage\nhttps://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0292131.g001&size=inline\n----------------\n----------------\npublishedAt\n2023-10-03T14:00:00Z\n----------------\n----------------\ncontent\nAbstract\nPharmacogenomic testing may be used to improve treatment outcomes and reduce the frequency of adverse drug reactions (ADRs). Population specific, targeted pharmacogenetics (PGx) panel-based… [+41646 chars]\n----------------\n#------------------------------------------\n# 56\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Soundandvision.com'}\n----------------\n----------------\nauthor\nThomas J. Norton\n----------------\n----------------\ntitle\nTelevision: The Way We Were\n----------------\n----------------\ndescription\nIn video, as in all things, you can't fully appreciate where you are, and where you're headed, without knowing where you've been. When I moved to the wilds of north Florida eight+ years ago I brought my two plasmas with me (a Pioneer Kuro and one of the last …\n----------------\n----------------\nurl\nhttps://www.soundandvision.com/content/television-way-we-were\n----------------\n----------------\nurlToImage\nhttps://www.soundandvision.com/images/Speaker%20Photo%201_0.jpg\n----------------\n----------------\npublishedAt\n2023-10-17T00:00:00Z\n----------------\n----------------\ncontent\nIn video, as in all things, you can't fully appreciate where you are, and where you're headed, without knowing where you've been. When I moved to the wilds of north Florida eight+ years ago I brought… [+7432 chars]\n----------------\n#------------------------------------------\n# 57\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAllied Market Research\n----------------\n----------------\ntitle\nGlobal Solid State Battery Market to Generate $3.4 Billion, by 2030 with 18.0% CAGR: Allied Market Research\n----------------\n----------------\ndescription\nThe global solid state battery market is experiencing growth due to surge in application of solid-state batteries in the wearable, drone, and healthcare sector. The global solid state battery market is experiencing growth due to surge in application of solid-…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/30/2769487/0/en/Global-Solid-State-Battery-Market-to-Generate-3-4-Billion-by-2030-with-18-0-CAGR-Allied-Market-Research.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/9c430095-89f7-48b4-b8f0-e1f4ed1a5660\n----------------\n----------------\npublishedAt\n2023-10-30T15:34:00Z\n----------------\n----------------\ncontent\nWilmington, DE , Oct. 30, 2023 (GLOBE NEWSWIRE) -- \nAllied Market Research published a report, titled, \"Solid State Battery Market by Application (Consumer and Portable Electronics, Electric Vehicle… [+5969 chars]\n----------------\n#------------------------------------------\n# 58\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nGlobal Market Insights Inc.\n----------------\n----------------\ntitle\nUrology Lasers Market to hit USD 2 billion by 2032, says Global Market Insights Inc.\n----------------\n----------------\ndescription\nUrology Lasers Industry is projected to witness a CAGR of 5.2 % during the period 2023-2032. This growth can be attributed to the increasing incidence of chronic and urological diseases. Urology Lasers Industry is projected to witness a CAGR of 5.2 % during t…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/31/2769924/0/en/Urology-Lasers-Market-to-hit-USD-2-billion-by-2032-says-Global-Market-Insights-Inc.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/6a29379b-a16f-4ee6-9798-26bdadb816f3\n----------------\n----------------\npublishedAt\n2023-10-31T09:30:00Z\n----------------\n----------------\ncontent\nSelbyville, Delaware, Oct. 31, 2023 (GLOBE NEWSWIRE) -- \nUrology Lasers Market size\n is expected to be worth USD 2 billion by 2032. The ongoing advancements in laser technology, including improved … [+5203 chars]\n----------------\n#------------------------------------------\n# 59\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAllied Market Research\n----------------\n----------------\ntitle\nSpain Health Insurance Third-Party Administrator Market to Reach $9,512.56 million by 2032 at 14.4% CAGR: Allied Market Research\n----------------\n----------------\ndescription\nSpain health insurance third-party administrator market is driven by the rise in need for effective claim handling & payment settlement, achieving operational efficiency & transparency in insurance business process, and adoption of third-party administrator i…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/31/2770028/0/en/Spain-Health-Insurance-Third-Party-Administrator-Market-to-Reach-9-512-56-million-by-2032-at-14-4-CAGR-Allied-Market-Research.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/9c430095-89f7-48b4-b8f0-e1f4ed1a5660\n----------------\n----------------\npublishedAt\n2023-10-31T11:18:00Z\n----------------\n----------------\ncontent\nWilmington, Delaware, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, Spain Health Insurance Third-Party Administrator Market by Insurance Service Type (Medical C… [+13187 chars]\n----------------\n#------------------------------------------\n# 60\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nSkyQuest Technology Consulting Pvt. Ltd.\n----------------\n----------------\ntitle\nPrescription Drugs Market to Surpass 2197 Billion by 2030 Drives Due to Growing Healthcare Needs\n----------------\n----------------\ndescription\nSkyQuest projects that the prescription drugs market will attain a USD 2197 billion value by 2030, with a CAGR of 8.9% over the forecast period (2023-2030). The global prescription drugs market is propelled by the rising demand for medications driven by aging…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/18/2762591/0/en/Prescription-Drugs-Market-to-Surpass-2197-Billion-by-2030-Drives-Due-to-Growing-Healthcare-Needs.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/c673c6fa-f0e7-47bf-8490-fe528c593820\n----------------\n----------------\npublishedAt\n2023-10-18T15:03:00Z\n----------------\n----------------\ncontent\nWestford, USA, Oct. 18, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest, the relentless progress in pharmaceutical research and technology fuels the creation of groundbreaking drugs and therapies, bro… [+5611 chars]\n----------------\n#------------------------------------------\n# 61\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Histalk2.com'}\n----------------\n----------------\nauthor\nMr. HIStalk\n----------------\n----------------\ntitle\nNews 10/20/23\n----------------\n----------------\ndescription\nTop News   OptumInsight CEO Neil de Crescenzo leaves the ...\n----------------\n----------------\nurl\nhttps://histalk2.com/2023/10/19/news-10-20-23/\n----------------\n----------------\nurlToImage\nNone\n----------------\n----------------\npublishedAt\n2023-10-19T20:48:45Z\n----------------\n----------------\ncontent\nTop News\n \nOptumInsight CEO Neil de Crescenzo leaves the company a year after it acquired Change Healthcare in a $13 billion deal, according to a LinkedIn post. He had been CEO of Change since 2013… [+11430 chars]\n----------------\n#------------------------------------------\n# 62\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAllied Market Research\n----------------\n----------------\ntitle\nDisposable Gloves Market Is Projected to Expand to Value of $29.80 Billion by 2030, Claims Allied Market Research\n----------------\n----------------\ndescription\nThe global disposable gloves market is experiencing growth due to numerous factors, including an increase in safety and hygiene concerns, technological advances, huge inflows of immigrants, and a growing awareness of hygiene issues among the food industry and…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/24/2765218/0/en/Disposable-Gloves-Market-Is-Projected-to-Expand-to-Value-of-29-80-Billion-by-2030-Claims-Allied-Market-Research.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/9c430095-89f7-48b4-b8f0-e1f4ed1a5660\n----------------\n----------------\npublishedAt\n2023-10-24T01:30:00Z\n----------------\n----------------\ncontent\nWilmington, Delaware, Oct. 23, 2023 (GLOBE NEWSWIRE) -- As per the exclusive report studied by Allied Market Research, the global disposable gloves industry is predicted to gain $29.80 billion by 203… [+7473 chars]\n----------------\n#------------------------------------------\n# 63\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAcumen Research and Consulting\n----------------\n----------------\ntitle\nAcrylic Adhesives Market to Reach USD 19.3 Billion by 2032, Growing at 5.9% CAGR\n----------------\n----------------\ndescription\nAcumen Research and Consulting recently published report titled “Acrylic Adhesives Market 2023 - 2032” Acumen Research and Consulting recently published report titled “Acrylic Adhesives Market 2023 - 2032”\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/25/2766130/0/en/Acrylic-Adhesives-Market-to-Reach-USD-19-3-Billion-by-2032-Growing-at-5-9-CAGR.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d\n----------------\n----------------\npublishedAt\n2023-10-25T00:00:00Z\n----------------\n----------------\ncontent\nBEIJING, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The Global Acrylic Adhesives Market Size accounted for USD 11.1 Billion in 2022 and is estimated to achieve a market size of USD 19.3 Billion by 2032 growin… [+8388 chars]\n----------------\n#------------------------------------------\n# 64\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAcumen Research and Consulting\n----------------\n----------------\ntitle\nPharmaceutical Contract Manufacturing Market to Reach USD 279.3 Billion by 2032, Growing at 6.8% CAGR\n----------------\n----------------\ndescription\nAcumen Research and Consulting recently published report titled “Pharmaceutical Contract Manufacturing Market 2023 - 2032” Acumen Research and Consulting recently published report titled “Pharmaceutical Contract Manufacturing Market 2023 - 2032”\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/23/2764810/0/en/Pharmaceutical-Contract-Manufacturing-Market-to-Reach-USD-279-3-Billion-by-2032-Growing-at-6-8-CAGR.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d\n----------------\n----------------\npublishedAt\n2023-10-23T13:11:00Z\n----------------\n----------------\ncontent\nLOS ANGELES, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The Global Pharmaceutical Contract Manufacturing Market Size accounted for USD 135.6 Billion in 2022 and is projected to achieve a market size of USD 27… [+9001 chars]\n----------------\n#------------------------------------------\n# 65\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nEastman Announces Third-Quarter 2023 Financial Results\n----------------\n----------------\ndescription\n(marketscreener.com) \nEastman Chemical Company announced its third-quarter 2023 financial results.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026078553/en/\n\nGenerated greater than $500 mill…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/EASTMAN-CHEMICAL-COMPANY-12448/news/Eastman-Announces-Third-Quarter-2023-Financial-Results-45164774/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdblanc.png\n----------------\n----------------\npublishedAt\n2023-10-26T20:19:02Z\n----------------\n----------------\ncontent\nEastman Chemical Company (NYSE:EMN) announced its third-quarter 2023 financial results.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202… [+11277 chars]\n----------------\n#------------------------------------------\n# 66\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Mercola.com'}\n----------------\n----------------\nauthor\ncommunities@mercola.com (Dr. Joseph Mercola)\n----------------\n AUTHOR ERROR: communities@mercolacom (dr joseph mercola)\n----------------\ntitle\nWhen Industry Values Profits Over Human Life\n----------------\n----------------\ndescription\nHumanity has both a good and an evil side, and in my eyes, war is the clearest embodiment of its evil. Unfortunately, war is typically out of sight and out of mind, so there is a general apathy towards the subject until it arrives at someone’s front door. \n\nS…\n----------------\n----------------\nurl\nhttps://articles.mercola.com/sites/articles/archive/2023/10/21/profits-over-human-life.aspx\n----------------\n----------------\nurlToImage\nhttps://media.mercola.com/ImageServer/Public/2023/October/FB/profits-over-human-life-fb.jpg\n----------------\n----------------\npublishedAt\n2023-10-21T00:00:00Z\n----------------\n----------------\ncontent\nMercola proudly supports these charities and organizations. View All \nDisclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual a… [+1007 chars]\n----------------\n#------------------------------------------\n# 67\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Steynonline.com'}\n----------------\n----------------\nauthor\nMark Steyn\n----------------\n----------------\ntitle\nFor Want of a Judge...\n----------------\n----------------\ndescription\nSo on Sunday I flew down to America's wretched capital city to prepare for this morning's jury selection in the case of Mann vs Steyn - the world's most worthless and longest-running defamation suit. And, as the flight landed and taxied toward the\n----------------\n----------------\nurl\nhttps://www.steynonline.com/13897/for-want-of-a-judge\n----------------\n----------------\nurlToImage\nhttps://www.steynonline.com/pics/7285.jpg\n----------------\n----------------\npublishedAt\n2023-10-30T09:26:00Z\n----------------\n----------------\ncontent\nSo on Sunday I flew down to America's wretched capital city to prepare for this morning's jury selection in the case of Mann vs Steyn - the world's most worthless and longest-running defamation suit.… [+9586 chars]\n----------------\n#------------------------------------------\n# 68\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Mercola.com'}\n----------------\n----------------\nauthor\ncommunities@mercola.com (Dr. Joseph Mercola)\n----------------\n AUTHOR ERROR: communities@mercolacom (dr joseph mercola)\n----------------\ntitle\nWhy Won't Doctors Innovate?\n----------------\n----------------\ndescription\nThroughout my medical career, I’ve known far too many struggling patients who have seen numerous doctors without getting any answers over what’s wrong with them. In many cases, once I meet the patient, it’s immediately apparent what the underlying issue is, w…\n----------------\n----------------\nurl\nhttps://articles.mercola.com/sites/articles/archive/2023/10/28/scientific-innovation.aspx\n----------------\n----------------\nurlToImage\nhttps://media.mercola.com/ImageServer/Public/2023/October/FB/scientific-innovation-fb.jpg\n----------------\n----------------\npublishedAt\n2023-10-28T00:00:00Z\n----------------\n----------------\ncontent\nMercola proudly supports these charities and organizations. View All \nDisclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual a… [+1007 chars]\n----------------\n#------------------------------------------\n# 69\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nRichardson Electronics, Ltd.\n----------------\n----------------\ntitle\nRichardson Electronics, Ltd. Receives Patent for Its Ultracapacitor Generator Start Module - ULTRAGEN3000™\n----------------\n----------------\ndescription\nNewly issued patent to support the Company's growth opportunities within energy storage solutions Newly issued patent to support the Company's growth opportunities within energy storage solutions\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/02/2752943/0/en/Richardson-Electronics-Ltd-Receives-Patent-for-Its-Ultracapacitor-Generator-Start-Module-ULTRAGEN3000.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/6819ae89-fc87-472f-a892-262c05e1a69f\n----------------\n----------------\npublishedAt\n2023-10-02T15:00:00Z\n----------------\n----------------\ncontent\nLAFOX, Ill., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Richardson Electronics, Ltd. (NASDAQ: RELL), a global provider of engineered solutions for renewable energy, is pleased to announce the issuance of U.S.… [+4291 chars]\n----------------\n#------------------------------------------\n# 70\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Mercola.com'}\n----------------\n----------------\nauthor\ncommunities@mercola.com (Dr. Joseph Mercola)\n----------------\n AUTHOR ERROR: communities@mercolacom (dr joseph mercola)\n----------------\ntitle\nHow Big Pharma Bought the Federal Government\n----------------\n----------------\ndescription\nFor a society to function, it requires a collective trust in the society’s institutions. One of the most challenging things for many to come to terms with throughout COVID-19 has been how each institution we trusted to protect us instead pushed a variety of u…\n----------------\n----------------\nurl\nhttps://articles.mercola.com/sites/articles/archive/2023/10/07/how-big-pharma-bought-the-federal-government.aspx\n----------------\n----------------\nurlToImage\nhttps://media.mercola.com/ImageServer/Public/2023/October/FB/how-big-pharma-bought-the-federal-government-fb.jpg\n----------------\n----------------\npublishedAt\n2023-10-07T00:00:00Z\n----------------\n----------------\ncontent\nMercola proudly supports these charities and organizations. View All \nDisclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual a… [+1007 chars]\n----------------\n#------------------------------------------\n# 71\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nMarketsandMarkets Research Pvt. Ltd.\n----------------\n----------------\ntitle\nMultimodal Imaging Market is Expected to Reach $5.5 billion | MarketsandMarkets.\n----------------\n----------------\ndescription\nChicago, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The multimodal imaging industry is poised for remarkable growth in the near future as technological advancements continue to converge and enhance diagnostic capabilities. Innovations in medical imaging, such as the i…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/03/2753620/0/en/Multimodal-Imaging-Market-is-Expected-to-Reach-5-5-billion-MarketsandMarkets.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/afcc5182-4ae0-43a8-a965-4351d590b7ed\n----------------\n----------------\npublishedAt\n2023-10-03T12:30:00Z\n----------------\n----------------\ncontent\nChicago, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The multimodal imaging industry is poised for remarkable growth in the near future as technological advancements continue to converge and enhance diagnostic… [+9386 chars]\n----------------\n#------------------------------------------\n# 72\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nBioNTech SE\n----------------\n----------------\ntitle\nBioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023\n----------------\n----------------\ndescription\nMAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE\n (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced follow-up data from its ongoing first-in-human Phase 1/2 trial (NCT04503278; 2019-004323-20) evaluating the safety and efficacy of th…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/23/2764948/0/en/BioNTech-Presents-Positive-Phase-1-2-Data-Update-for-CAR-T-Cell-Therapy-Candidate-BNT211-in-Advanced-Solid-Tumors-at-ESMO-Congress-2023.html\n----------------\n----------------\nurlToImage\nhttps://ml-eu.globenewswire.com/Resource/Download/b9e2e00e-f790-4d54-a01f-4c85716b01bd\n----------------\n----------------\npublishedAt\n2023-10-23T15:30:00Z\n----------------\n----------------\ncontent\n&lt;ul&gt;&lt;li&gt;BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding… [+9496 chars]\n----------------\n#------------------------------------------\n# 73\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nSS Innovations International, Inc.\n----------------\n----------------\ntitle\nSS Innovations Launches Innovative Robotic Cardiac Surgery Program in India\n----------------\n----------------\ndescription\nDr. Sudhir Srivastava, a world-leading cardiac surgeon, performed the world’s first beating heart robotic cardiac bypass surgery using the SSi Mantra Surgical Robotic System\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/03/2753654/0/en/SS-Innovations-Launches-Innovative-Robotic-Cardiac-Surgery-Program-in-India.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/d8c18bbf-e8e4-4d8a-909c-498abfdaa4d0\n----------------\n----------------\npublishedAt\n2023-10-03T12:34:00Z\n----------------\n----------------\ncontent\nDr. Sudhir Srivastava, a world-leading cardiac surgeon, performed the worlds first beating heart robotic cardiac bypass surgery using the SSi Mantra Surgical Robotic System\nFORT LAUDERDALE, FL, Oct.… [+6012 chars]\n----------------\n#------------------------------------------\n# 74\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nSS Innovations International, Inc.\n----------------\n----------------\ntitle\nUpdate: SS Innovations Launches Innovative Robotic Cardiac Surgery Program in India\n----------------\n----------------\ndescription\nDr. Sudhir Srivastava, a world-leading cardiac surgeon, performed the world’s first beating heart robotic cardiac bypass surgery using the SSi Mantra Surgical Robotic System\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/03/2753838/0/en/Update-SS-Innovations-Launches-Innovative-Robotic-Cardiac-Surgery-Program-in-India.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/d8c18bbf-e8e4-4d8a-909c-498abfdaa4d0\n----------------\n----------------\npublishedAt\n2023-10-03T14:00:00Z\n----------------\n----------------\ncontent\nDr. Sudhir Srivastava, a world-leading cardiac surgeon, performed the worlds first beating heart robotic cardiac bypass surgery using the SSi Mantra Surgical Robotic System\nFORT LAUDERDALE, FL, Oct.… [+6021 chars]\n----------------\n#------------------------------------------\n# 75\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nCMI MARKET RESEARCH PRIVATE LIMITED\n----------------\n----------------\ntitle\n[Latest] Global Cannabidiol Market Size/Share Worth USD 19.67 Billion by 2032 at a 18% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)\n----------------\n----------------\ndescription\n[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cannabidiol Market size & share revenue was valued at approximately USD 17.50 Billion in 2022 and is expected to reach USD 17.71…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/26/2767080/0/en/Latest-Global-Cannabidiol-Market-Size-Share-Worth-USD-19-67-Billion-by-2032-at-a-18-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentation-Growth-.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/74609d89-5437-4826-b7b8-31238ea2e65c\n----------------\n----------------\npublishedAt\n2023-10-26T04:30:00Z\n----------------\n----------------\ncontent\nAustin, TX, USA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled Cannabidiol Market Size, Trends and Insights By Source Type (Hemp, Marijuana), By … [+23047 chars]\n----------------\n#------------------------------------------\n# 76\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nNovartis Pharma  AG\n----------------\n----------------\ntitle\nNovartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer\n----------------\n----------------\ndescription\nBasel, October 20, 2023 — Novartis will present late-breaking results from a prespecified exploratory subgroup analysis of invasive disease-free survival (iDFS) from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congr…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/20/2763906/0/en/Novartis-Kisqali-NATALEE-analysis-reinforces-consistent-reduction-in-risk-of-recurrence-across-key-subgroups-of-patients-with-early-breast-cancer.html\n----------------\n----------------\nurlToImage\nhttps://ml-eu.globenewswire.com/Resource/Download/5d242013-5d1f-440c-8ba6-3b5d3799b035\n----------------\n----------------\npublishedAt\n2023-10-20T10:00:00Z\n----------------\n----------------\ncontent\n&lt;ul&gt;&lt;li&gt;Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tu… [+21162 chars]\n----------------\n#------------------------------------------\n# 77\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'The Times of Israel'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nTop 10 Best Liver Supplements: Most Effective Liver Detox Pills That Work - Sponsored Content\n----------------\n----------------\ndescription\nSponsored Content\n----------------\n----------------\nurl\nhttps://www.timesofisrael.com/spotlight/top-10-best-liver-supplements-most-effective-liver-detox-pills-that-work/\n----------------\n----------------\nurlToImage\nhttps://static.timesofisrael.com/www/images/toi_icon_fb_1200.png\n----------------\n----------------\npublishedAt\n2023-10-22T04:59:11Z\n----------------\n----------------\ncontent\nDespite its importance, one often overlooked aspect of our wellness is the health of our liver. This vital organ is responsible for purifying our body of toxins and plays a vital role in the breakdow… [+37367 chars]\n----------------\n#------------------------------------------\n# 78\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nStraits Research\n----------------\n----------------\ntitle\nMagnetic Sensor Market Size Is Projected to Grow at A CAGR Of 6.68% By 2030, Powered by Rising Investments and Notable Technological Advancements\n----------------\n----------------\ndescription\nMagnetic sensor manufacturers are increasing their investments in various magnetic sensing technologies, such as 3D sensing, tunnel magnetoresistance (TMR), and giant magnetoresistance (GMR), to strengthen their domain expertise and market position. Magnetic …\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/26/2767928/0/en/Magnetic-Sensor-Market-Size-Is-Projected-to-Grow-at-A-CAGR-Of-6-68-By-2030-Powered-by-Rising-Investments-and-Notable-Technological-Advancements.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/c25b8e5a-9a9f-499a-8eb6-76ff0d860959\n----------------\n----------------\npublishedAt\n2023-10-26T18:15:00Z\n----------------\n----------------\ncontent\nNew York, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Electronic control systems in both commercial and passenger vehicles are composed of magnetic sensors. As a result of the fact that these sy… [+6679 chars]\n----------------\n#------------------------------------------\n# 79\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nResearch and Markets\n----------------\n----------------\ntitle\nGlobal Contract Research And Manufacturing Services (CRAMS) Markets, 2017-2022, 2022-2027F, 2032F: From Clinical Trials to Commercialization - The CRAMS Advantage in Modern Medicine\n----------------\n----------------\ndescription\nDublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The \"Contract Research And Manufacturing Services (CRAMS) Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.The global contract research and manufacturing services (crams) market gr…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/02/2752512/28124/en/Global-Contract-Research-And-Manufacturing-Services-CRAMS-Markets-2017-2022-2022-2027F-2032F-From-Clinical-Trials-to-Commercialization-The-CRAMS-Advantage-in-Modern-Medicine.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\n----------------\n----------------\npublishedAt\n2023-10-02T08:43:00Z\n----------------\n----------------\ncontent\nDublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The \"Contract Research And Manufacturing Services (CRAMS) Global Market Report 2023\" report has been added to ResearchAndMarkets.com's offering.The global co… [+6019 chars]\n----------------\n#------------------------------------------\n# 80\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nNovartis Pharma  AG\n----------------\n----------------\ntitle\nNovartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting\n----------------\n----------------\ndescription\nBasel, October 23, 2023 — Novartis today presents data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxe…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/23/2764889/0/en/Novartis-Pluvicto-shows-clinically-meaningful-and-highly-statistically-significant-rPFS-benefit-in-patients-with-PSMA-positive-metastatic-castration-resistant-prostate-cancer-in-th.html\n----------------\n----------------\nurlToImage\nhttps://ml-eu.globenewswire.com/Resource/Download/5d242013-5d1f-440c-8ba6-3b5d3799b035\n----------------\n----------------\npublishedAt\n2023-10-23T14:30:00Z\n----------------\n----------------\ncontent\n&lt;ul&gt;&lt;li&gt;Phase III PSMAfore trial with Pluvictomet its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per u… [+18638 chars]\n----------------\n#------------------------------------------\n# 81\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAcumen Research and Consulting\n----------------\n----------------\ntitle\nHealthcare Chatbots Market is forecasted to reach USD 1,615.2 Million by 2032, growing at a CAGR of 18.3% from 2023 to 2032\n----------------\n----------------\ndescription\nAcumen Research and Consulting recently published report titled “Healthcare Chatbots Market Forecast, 2023 - 2032” Acumen Research and Consulting recently published report titled “Healthcare Chatbots Market Forecast, 2023 - 2032”\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/05/2755852/0/en/Healthcare-Chatbots-Market-is-forecasted-to-reach-USD-1-615-2-Million-by-2032-growing-at-a-CAGR-of-18-3-from-2023-to-2032.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908452c1-dc89-4765-93b2-c92a8f7b6f2d\n----------------\n----------------\npublishedAt\n2023-10-05T23:00:00Z\n----------------\n----------------\ncontent\nTOKYO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The Healthcare Chatbots Market is at the cutting edge of healthcare technology, offering advanced solutions for enhancing patient care and healthcare services… [+9463 chars]\n----------------\n#------------------------------------------\n# 82\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAllied Market Research\n----------------\n----------------\ntitle\nBiosurgery Market is Projected to Reach an Estimate of $27,324.80 Million by 2030, With CAGR of 9.1%: Allied Market Research\n----------------\n----------------\ndescription\nThe global biosurgery market is experiencing growth due to various factors such as an increase in the prevalence of chronic disease, a surge in the number of surgical procedures, and a strong emphasis on research and development activities, resulting in the l…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/27/2768116/0/en/Biosurgery-Market-is-Projected-to-Reach-an-Estimate-of-27-324-80-Million-by-2030-With-CAGR-of-9-1-Allied-Market-Research.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/9c430095-89f7-48b4-b8f0-e1f4ed1a5660\n----------------\n----------------\npublishedAt\n2023-10-27T01:00:00Z\n----------------\n----------------\ncontent\nWilmington, Delaware, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allied Market Research released a report, titled, \"Biosurgery Market by Product Type (Mesh, Anti Adhesive Agents, Hemostatic and Surgical Seala… [+7448 chars]\n----------------\n#------------------------------------------\n# 83\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nResearch and Markets\n----------------\n----------------\ntitle\nGlobal Hospital Information Systems (HIS) Strategic Business Report 2023: Market to Reach $116.2 Billion by 2030 - Digital Health Investments Exhibit Solid Trajectory, Providing Growth Opportunities\n----------------\n----------------\ndescription\nDublin, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The \"Hospital Information Systems (HIS) - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.Global Hospital Information Systems (HIS) Market to Reach $116.2 Billion by 2030Th…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/27/2768224/28124/en/Global-Hospital-Information-Systems-HIS-Strategic-Business-Report-2023-Market-to-Reach-116-2-Billion-by-2030-Digital-Health-Investments-Exhibit-Solid-Trajectory-Providing-Growth-Op.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\n----------------\n----------------\npublishedAt\n2023-10-27T09:28:00Z\n----------------\n----------------\ncontent\nDublin, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The \"Hospital Information Systems (HIS) - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.\nGlobal Hospital Info… [+7372 chars]\n----------------\n#------------------------------------------\n# 84\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nFuture Market Insights Global and Consulting Pvt. Ltd.\n----------------\n----------------\ntitle\neClinical Solutions and Software Market Poised to Achieve ~US$ 29.1 Billion Valuation by 2033 | Future Market Insights, Inc.\n----------------\n----------------\ndescription\nThe eClinical solutions and software market is a dynamic and evolving sector that plays a crucial role in advancing clinical research and drug development through digital technologies and software solutions. The eClinical solutions and software market is a dy…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/25/2766679/0/en/eClinical-Solutions-and-Software-Market-Poised-to-Achieve-US-29-1-Billion-Valuation-by-2033-Future-Market-Insights-Inc.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/915d2f9c-7dc6-40c7-995c-2ba168208baa\n----------------\n----------------\npublishedAt\n2023-10-25T14:00:00Z\n----------------\n----------------\ncontent\nNEWARK, Del, Oct. 25, 2023 (GLOBE NEWSWIRE) -- By the end of 2023, the global eClinical solutions and software market is projected to be valued at US$ 9.3 billion, and by 2033, it is projected to gro… [+8026 chars]\n----------------\n#------------------------------------------\n# 85\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Activistpost.com'}\n----------------\n----------------\nauthor\nActivist Post\n----------------\n----------------\ntitle\nThe Complicity of Compliance\n----------------\n----------------\ndescription\nBy Robin Koerner We live in an age of agendas. In the pursuit of them, behaviors that are otherwise deemed unacceptable supposedly become acceptable or...\nThe Complicity of Compliance\n----------------\n----------------\nurl\nhttps://www.activistpost.com/2023/10/the-complicity-of-compliance.html\n----------------\n----------------\nurlToImage\nhttps://www.activistpost.com/wp-content/uploads/2023/10/compliance-bi.png\n----------------\n----------------\npublishedAt\n2023-10-15T16:35:56Z\n----------------\n----------------\ncontent\nBy Robin Koerner\nWe live in an age of agendas.\nIn the pursuit of them, behaviors that are otherwise deemed unacceptable supposedly become acceptable or even necessary. Justified by them, what is ot… [+18881 chars]\n----------------\n#------------------------------------------\n# 86\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nResearch and Markets\n----------------\n----------------\ntitle\nGlobal Radiopharmaceuticals Strategic Analysis Report 2023: Market to Reach $14.3 Billion by 2030 - Emergence of Radiotheranostics as Dual-Functioning Radiopharmaceuticals Bolsters Growth\n----------------\n----------------\ndescription\nDublin, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The \"Radiopharmaceuticals - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.Global Radiopharmaceuticals Market to Reach $14.3 Billion by 2030The global market for Radiophar…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/09/2756523/28124/en/Global-Radiopharmaceuticals-Strategic-Analysis-Report-2023-Market-to-Reach-14-3-Billion-by-2030-Emergence-of-Radiotheranostics-as-Dual-Functioning-Radiopharmaceuticals-Bolsters-Gro.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\n----------------\n----------------\npublishedAt\n2023-10-09T09:48:00Z\n----------------\n----------------\ncontent\nDublin, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The \"Radiopharmaceuticals - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.\nGlobal Radiopharmaceuticals Market… [+9856 chars]\n----------------\n#------------------------------------------\n# 87\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nRoctool S A : 20231012 Roctool RH2 ENG\n----------------\n----------------\ndescription\n(marketscreener.com) \n \n Press Release\n \n \n 12th October 2023 - 6:00pm CEST\n \n \n HALF YEAR RESULTS 2023\n \n \n \n Sales growth of 24 %\n \n \n Positive EBITDA\n \n \n Stable Cash Position\n \n \n \n Roctool , specialists in mold heating and...https://www.marketscreener.co…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/ROCTOOL-S-A-14912735/news/Roctool-S-A-20231012-Roctool-RH2-ENG-45052265/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdblanc.png\n----------------\n----------------\npublishedAt\n2023-10-12T16:09:03Z\n----------------\n----------------\ncontent\nPress Release\n12th October 2023 - 6:00pm CEST\nHALF YEAR RESULTS 2023\n&lt;ul&gt;&lt;li&gt;\n Sales growth of 24 %&lt;/li&gt;&lt;li&gt;\n Positive EBITDA&lt;/li&gt;&lt;li&gt;\n Stable Cash Position&lt;/li&gt;&lt;/ul&gt;\nRoctool (Euronext Growth … [+6027 chars]\n----------------\n#------------------------------------------\n# 88\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nROCTOOL: ROCTOOL: HALF YEAR RESULTS 2023\n----------------\n----------------\ndescription\n(marketscreener.com) \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nROCTOOL\n\nROCTOOL: ROCTOOL: HALF YEAR RESULTS 2023 12-Oct-2023 / 18:06 CET/CEST\n\nDissemination of a French Regulatory News, transmitted by EQS Group.\n\nThe issuer is solely responsible for the content of this announcement.\n\n…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/ROCTOOL-S-A-14912735/news/ROCTOOL-ROCTOOL-HALF-YEAR-RESULTS-2023-45052256/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdnoir.png\n----------------\n----------------\npublishedAt\n2023-10-12T16:08:02Z\n----------------\n----------------\ncontent\n12-Oct-2023 / 18:06 CET/CESTDissemination of a French Regulatory News, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.Press Release\n12thOctober2023 6:… [+5932 chars]\n----------------\n#------------------------------------------\n# 89\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Plos.org'}\n----------------\n----------------\nauthor\nJos G. A. Smits, Dulce Lima Cunha, Maryam Amini, Marina Bertolin, Camille Laberthonnière, Jieqiong Qu, Nicholas Owen, Lorenz Latta, Berthold Seitz, Lauriane N. Roux, Tanja Stachon, Stefano Ferrari, Mariya Moosajee, Daniel Aberdam, Nora Szentmary, Simon J. van Heeringen, Huiqing Zhou\n----------------\n----------------\ntitle\nIdentification of the regulatory circuit governing corneal epithelial fate determination and disease\n----------------\n----------------\ndescription\nThis study uses multiomics and gene regulatory network analysis to compare the limbal stem cells that maintain the cornea with keratinocytes which maintain the skin, revealing an intriguing interplay of transcription factors that drive epithelial similarities…\n----------------\n----------------\nurl\nhttps://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002336\n----------------\n----------------\nurlToImage\nhttps://journals.plos.org/plosbiology/article/figure/image?id=10.1371/journal.pbio.3002336.g006&size=inline\n----------------\n----------------\npublishedAt\n2023-10-19T14:00:00Z\n----------------\n----------------\ncontent\nCitation: Smits JGA, Cunha DL, Amini M, Bertolin M, Laberthonnière C, Qu J, et al. (2023) Identification of the regulatory circuit governing corneal epithelial fate determination and disease. PLoS Bi… [+88932 chars]\n----------------\n#------------------------------------------\n# 90\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nResearch and Markets\n----------------\n----------------\ntitle\nGlobal Polyolefins Strategic Research Report 2023-2030: Innovative Technologies to Enable Diverse Spectrum of Tailored, Next-Gen Polyolefins, New Approach to Facilitate Up-Cycling of Polyolefin\n----------------\n----------------\ndescription\nDublin, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The \"Polyolefins - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.Global Polyolefins Market to Reach $458.1 Billion by 2030The global market for Polyolefins estimated at U…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/27/2768454/28124/en/Global-Polyolefins-Strategic-Research-Report-2023-2030-Innovative-Technologies-to-Enable-Diverse-Spectrum-of-Tailored-Next-Gen-Polyolefins-New-Approach-to-Facilitate-Up-Cycling-of-.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\n----------------\n----------------\npublishedAt\n2023-10-27T13:23:00Z\n----------------\n----------------\ncontent\nDublin, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The \"Polyolefins - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.\nGlobal Polyolefins Market to Reach $458.1 B… [+9472 chars]\n----------------\n#------------------------------------------\n# 91\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Marketscreener.com'}\n----------------\n----------------\nauthor\nNone\n----------------\nERROR\n----------------\ntitle\nGold Reserve : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K\n----------------\n----------------\ndescription\n(marketscreener.com) \n NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS\n \n \n NOTICE IS HEREBY GIVEN that an annual general meeting of the holders of Class A common shares of GOLD RESERVE INC. will be held at 999 W. Riverside Avenue, Suite 401, Spokane, Washin…\n----------------\n----------------\nurl\nhttps://www.marketscreener.com/quote/stock/GOLD-RESERVE-INC-120788720/news/Gold-Reserve-NOTICE-OF-ANNUAL-GENERAL-MEETING-OF-SHAREHOLDERS-Form-6-K-45175795/\n----------------\n----------------\nurlToImage\nhttps://www.marketscreener.com/images/twitter_MS_fdblanc.png\n----------------\n----------------\npublishedAt\n2023-10-27T17:33:03Z\n----------------\n----------------\ncontent\nNOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS\nNOTICE IS HEREBY GIVEN that an annual general meeting (the \"Meeting\") of the holders (the \"Shareholders\") of Class A common shares (the \"Class A Shar… [+154046 chars]\n----------------\n#------------------------------------------\n# 92\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'Activistpost.com'}\n----------------\n----------------\nauthor\nActivist Post\n----------------\n----------------\ntitle\nCostco Is SELLING OUT of Gold Bars — The Economic Crisis Can No Longer Be Hidden\n----------------\n----------------\ndescription\nBy Daisy Luther These days, at Costco, it seems like you can get whatever you need for the Zombie Apocalypse. A savvy shopper can purchase...\nCostco Is SELLING OUT of Gold Bars — The Economic Crisis Can No Longer Be Hidden\n----------------\n----------------\nurl\nhttps://www.activistpost.com/2023/10/costco-is-selling-out-of-gold-bars-the-economic-crisis-can-no-longer-be-hidden.html\n----------------\n----------------\nurlToImage\nhttps://www.activistpost.com/wp-content/uploads/2023/10/costco-gold-1024x536-1.jpg\n----------------\n----------------\npublishedAt\n2023-10-06T12:56:13Z\n----------------\n----------------\ncontent\nBy Daisy Luther\nThese days, at Costco, it seems like you can get whatever you need for the Zombie Apocalypse. A savvy shopper can purchase anything from a massive bulk pack of toilet paper they can … [+8814 chars]\n----------------\n#------------------------------------------\n# 93\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'We-heart.com'}\n----------------\n----------------\nauthor\nKire Stojkovski M.D\n----------------\n----------------\ntitle\nA Comprehensive Guide to the Best Sex Pills for Men\n----------------\n----------------\ndescription\nFacing challenges in your intimate moments can be both mentally and physically taxing for men. But with an array of products that promise to boost confidence and performance, how do you decide which one will work best for you? This article aims to provide a c…\n----------------\n----------------\nurl\nhttps://www.we-heart.com/2023/10/30/best-male-enhancement-pills/\n----------------\n----------------\nurlToImage\nhttps://www.we-heart.com/upload-images/maleenhancementpills2.jpg\n----------------\n----------------\npublishedAt\n2023-10-30T14:39:43Z\n----------------\n----------------\ncontent\nFacing challenges in your intimate moments can be both mentally and physically taxing for men. But with an array of products that promise to boost confidence and performance, how do you decide which … [+30392 chars]\n----------------\n#------------------------------------------\n# 94\n#------------------------------------------\n----------------\nsource\n{'id': 'usa-today', 'name': 'USA Today'}\n----------------\n----------------\nauthor\nRobert Zeglinski\n----------------\n----------------\ntitle\nNFL trade deadline: 17 top players who could be available in a deal (Derrick Henry!)\n----------------\n----------------\ndescription\nDerrick Henry is just one of many NFL names who could be traded soon.\n----------------\n----------------\nurl\nhttps://ftw.usatoday.com/lists/nfl-trade-deadline-2023-top-players-available-derrick-henry-brian-burns\n----------------\n----------------\nurlToImage\nhttps://ftw.usatoday.com/wp-content/uploads/sites/90/2019/11/usp-nfl_-jacksonville-jaguars-at-tennessee-titans-e1698259457626.jpg?w=1024&h=576&crop=1\n----------------\n----------------\npublishedAt\n2023-10-26T11:00:25Z\n----------------\n----------------\ncontent\nWe are past the days of the NFL trade deadline being a dormant period of inactivity.\nIn recent years, general managers and head coaches have clearly realized it isn’t that hard to integrate new play… [+9681 chars]\n----------------\n#------------------------------------------\n# 95\n#------------------------------------------\n----------------\nsource\n{'id': 'new-york-magazine', 'name': 'New York Magazine'}\n----------------\n----------------\nauthor\nBy Reeves Wiedeman\n----------------\n----------------\ntitle\nShams Charania’s Scoop Dreams\n----------------\n----------------\ndescription\nShams Charania has spent a decade texting and tweeting his way to the top of the NBA reporting world. Now the senior NBA insider for The Athletic, he might be the future of sports journalism.\n----------------\n----------------\nurl\nhttp://nymag.com/intelligencer/article/shams-charania-nba-insider-the-athletic-new-york-times-profile.html\n----------------\n----------------\nurlToImage\nhttps://pyxis.nymag.com/v1/imgs/7ae/31f/70a13460369be76df36ea7216f99a63835-NYMAG-ShamsCharania-EvanJenkins-1.1x.rsocial.w1200.jpg\n----------------\n----------------\npublishedAt\n2023-10-11T12:00:35Z\n----------------\n----------------\ncontent\nShams Charania arrived at a restaurant in downtown Chicago last month just as his colleagues and sources around the National Basketball Association told me he would: running a bit late, phone in hand… [+38845 chars]\n----------------\n#------------------------------------------\n# 96\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nResearch and Markets\n----------------\n----------------\ntitle\nSilicone and Polyurethane Sealants Lead the Pack with Strong Growth Prospects in the Global Market\n----------------\n----------------\ndescription\nDublin, Oct.  02, 2023  (GLOBE NEWSWIRE) -- The \"Sealants - Global Strategic Business Report\" report has been added to  ResearchAndMarkets.com's offering....\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/02/2752841/28124/en/Silicone-and-Polyurethane-Sealants-Lead-the-Pack-with-Strong-Growth-Prospects-in-the-Global-Market.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\n----------------\n----------------\npublishedAt\n2023-10-02T13:18:00Z\n----------------\n----------------\ncontent\nDublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The \"Sealants - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com's offering.\nThe global Sealants market is poised for impre… [+11752 chars]\n----------------\n#------------------------------------------\n# 97\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nKeystone Dental Group\n----------------\n----------------\ntitle\nKeystone Dental Group Granted Patent from USPTO for Nexus IOS Solution\n----------------\n----------------\ndescription\nNexus iOS Scan Gauge solution is the only patented elongated body scan apparatus available on the market that acquires direct implant-location data Nexus iOS Scan Gauge solution is the only patented elongated body scan apparatus available on the market that a…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/18/2762740/0/en/Keystone-Dental-Group-Granted-Patent-from-USPTO-for-Nexus-IOS-Solution.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/2f1ef631-0cd8-4120-ad73-68fad1478a32\n----------------\n----------------\npublishedAt\n2023-10-18T20:05:00Z\n----------------\n----------------\ncontent\nIRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings (Keystone Dental or the Company), today announced the United States Patent and Trademark Off… [+12576 chars]\n----------------\n#------------------------------------------\n# 98\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'We-heart.com'}\n----------------\n----------------\nauthor\nTory Lawrence\n----------------\n----------------\ntitle\nBuy High-Yield Marijuana Seeds for Sale With US Shipping\n----------------\n----------------\ndescription\nYou’ve done your research on feminized cannabis seeds, autoflowering cannabis seeds, and regular seeds. And now you feel it’s about time you took the plunge: ordered your package of cannabis seeds. But, for some reason, something’s holding you back still. Whi…\n----------------\n----------------\nurl\nhttps://www.we-heart.com/2023/10/03/marijuana-seeds-for-sale-uk/\n----------------\n----------------\nurlToImage\nhttps://www.we-heart.com/upload-images/buymarijuanaseedsuk2.jpg\n----------------\n----------------\npublishedAt\n2023-10-03T15:30:45Z\n----------------\n----------------\ncontent\nYouve done your research on feminized cannabis seeds, autoflowering cannabis seeds, and regular seeds.\nAnd now you feel its about time you took the plunge: ordered your package of cannabis seeds.\nB… [+28092 chars]\n----------------\n#------------------------------------------\n# 99\n#------------------------------------------\n----------------\nsource\n{'id': None, 'name': 'GlobeNewswire'}\n----------------\n----------------\nauthor\nAllied Market Research\n----------------\n----------------\ntitle\nPoint of Care Diagnostics Market Is Projected to Gain $55,275.73 Million by 2030, Claims Allied Market Research\n----------------\n----------------\ndescription\nThe global point of care diagnostics market growth is attributed to the rise in the prevalence of chronic diseases and several helpful initiatives administered by government and non-governmental organizations. The global point of care diagnostics market growt…\n----------------\n----------------\nurl\nhttps://www.globenewswire.com/news-release/2023/10/27/2768455/0/en/Point-of-Care-Diagnostics-Market-Is-Projected-to-Gain-55-275-73-Million-by-2030-Claims-Allied-Market-Research.html\n----------------\n----------------\nurlToImage\nhttps://ml.globenewswire.com/Resource/Download/9c430095-89f7-48b4-b8f0-e1f4ed1a5660\n----------------\n----------------\npublishedAt\n2023-10-27T13:24:00Z\n----------------\n----------------\ncontent\nWilmington, Delaware, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, \"Point of Care Diagnostics Market by Product (Cholesterol Test Strips, Glucose Moni… [+8581 chars]\n----------------\n\n\n\n\n\n\n\n\n\ntitle\ndescription\n\n\n\n\n0\na round-up of the talks from gaconf usa 2023\ngaconf returned to the us this week with a ser...\n\n\n1\namerican can prevent (and control) type 2 diab...\nusa today's health team spoke with scores of e...\n\n\n2\nthe steep cost of type 2: when diabetes dragge...\nthe nation's disjointed and confusing health c...\n\n\n3\na hidden system of exploitation underpins us h...\nthis series was produced in partnership with t...\n\n\n4\nthe childcare cliff: $122 billion dollar crisi...\nthe childcare crisis in america; the harsh tru..."
  },
  {
    "objectID": "Data_Exploration.html",
    "href": "Data_Exploration.html",
    "title": "Data Exploration",
    "section": "",
    "text": "In the Exploratory Data Analysis (EDA) section, we leverage the capabilities of R, complemented by the ggplot2 package, to perform an in-depth exploration of the dataset. EDA encompasses various crucial components, including Data Understanding, which lays the groundwork for grasping the dataset’s characteristics and structure. Descriptive Statistics provide a concise summary and quantitative description of the dataset’s main features. Data Visualization is employed to represent the data graphically, ensuring a clear and intuitive understanding of the underlying patterns and trends. Correlation Analysis is conducted to discern the relationships and dependencies between different variables. Hypothesis Generation allows us to formulate assumptions and predictions based on the observed patterns, guiding further investigation. Lastly, Identifying Outliers is an essential step to detect and address any anomalous data points that might distort the analysis results. Together, these elements constitute a comprehensive EDA process, ensuring a robust foundation for subsequent analyses and decision-making."
  },
  {
    "objectID": "Data_Exploration.html#data-understand",
    "href": "Data_Exploration.html#data-understand",
    "title": "Data Exploration",
    "section": "Data Understand",
    "text": "Data Understand\nFor this project, we are working with four distinct datasets. Our aim is to gain a comprehensive understanding of the characteristics associated with each feature, including their data types, relationships, and relevance to the project at hand. To achieve this, we will engage in Exploratory Data Analysis (EDA), which will enable us to delve deeper into the nuances of the datasets and extract valuable insights. To focus on EDA, we are only selecting one dataset.\n\n\nCode\nlibrary(tidyverse)\nlibrary(tidyquant)\nlibrary(ggplot2)\nlibrary(forecast)\nlibrary(astsa) \nlibrary(xts)\nlibrary(tseries)\nlibrary(lubridate)\nlibrary(plotly)\nlibrary(dplyr)\n\n#load df\nihe_df &lt;- read.csv(\"cleaned_data/IHE.csv\")"
  },
  {
    "objectID": "Data_Exploration.html#descriptive-statistics",
    "href": "Data_Exploration.html#descriptive-statistics",
    "title": "Data Exploration",
    "section": "Descriptive Statistics",
    "text": "Descriptive Statistics\nDescriptive statistics involve computing and presenting fundamental summary metrics, including the mean, median, mode, standard deviation, and variance, specifically for numerical variables. To gain an initial understanding of the IHE stock market dataset, we can display its first few entries and subsequently delve into these summary statistics. In the case of categorical variables, bar charts prove to be an effective tool for visualizing the distribution of the data.\nThe IHE dataset comprises time-series data, presenting numerical information in a structured format. It is pertinent to note that this dataset specifically pertains to stock market data of IHE, spanning from October 2019 through October 2023.\n\n\nCode\nhead(ihe_df)\n\nsummary(ihe_df)\n\nihe_df$Date = as.Date(ihe_df$Date)\n\n\n\nA data.frame: 6 × 7\n\n\n\nDate\nOpen\nHigh\nLow\nClose\nAdj.Close\nVolume\n\n\n\n&lt;chr&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;int&gt;\n\n\n\n\n1\n2019-10-09\n137.73\n138.39\n137.73\n138.06\n129.2299\n7600\n\n\n2\n2019-10-10\n137.73\n138.54\n137.73\n138.06\n129.2299\n6300\n\n\n3\n2019-10-11\n139.49\n141.05\n139.49\n140.12\n131.1581\n19200\n\n\n4\n2019-10-14\n139.72\n140.37\n139.72\n139.79\n130.8493\n4500\n\n\n5\n2019-10-15\n141.11\n142.89\n141.11\n142.43\n133.3204\n193500\n\n\n6\n2019-10-16\n142.80\n143.90\n142.80\n142.98\n133.8353\n14200\n\n\n\n\n\n     Date                Open            High            Low       \n Length:1006        Min.   :120.8   Min.   :122.0   Min.   :115.5  \n Class :character   1st Qu.:166.1   1st Qu.:167.1   1st Qu.:165.0  \n Mode  :character   Median :180.5   Median :181.4   Median :179.7  \n                    Mean   :176.2   Mean   :177.2   Mean   :175.2  \n                    3rd Qu.:187.3   3rd Qu.:188.2   3rd Qu.:186.4  \n                    Max.   :201.7   Max.   :202.8   Max.   :201.1  \n     Close         Adj.Close         Volume      \n Min.   :117.0   Min.   :109.9   Min.   :  1200  \n 1st Qu.:166.0   1st Qu.:157.2   1st Qu.:  3900  \n Median :180.7   Median :175.7   Median :  6100  \n Mean   :176.2   Mean   :170.1   Mean   : 11116  \n 3rd Qu.:187.3   3rd Qu.:182.7   3rd Qu.: 11200  \n Max.   :201.8   Max.   :196.2   Max.   :227600  \n\n\nThe summary of basic statistics provided above showcases a comprehensive range of measures including the minimum, first quartile, median, mean, third quartile, and maximum values. The dataset encompasses a variety of stock-related information, covering aspects such as date, opening and closing prices, lowest and highest prices, adjusted closing price, and the volume of stocks traded. Upon examination of the dataset, it is evident that the stock-related data is entirely numerical in nature, which leads us to conclude that there are no categorical variables present in this particular dataset."
  },
  {
    "objectID": "Data_Exploration.html#data-visualization",
    "href": "Data_Exploration.html#data-visualization",
    "title": "Data Exploration",
    "section": "Data Visualization",
    "text": "Data Visualization\nBy leveraging visualizations like histograms, box plots, scatter plots, and line plots, we can conduct a thorough exploration of the data’s distribution, the interrelationships between variables, and any potential patterns or trends that may emerge. Specifically, in our scenario, we are examining time series data related to the stock market. Consequently, we are utilizing line plots, and potentially lag plots as well, to delve into correlations and gain deeper insights.\nThe stock market data from IHE are sequential, constituting a time series. Thus, it is imperative to confirm that the dataset remains stationary. Following this, in the Naive Bayes section, we will proceed to partition the data into training and testing sets. This step is crucial as it enables us to validate the model’s performance and ensure its reliability for subsequent in-depth analysis.\n\n\nCode\nihe_plot = ggplot(ihe_df, aes(x=Date))+ geom_line(aes(y=Adj.Close))+ xlab(\"Year\")+ ylab(\"Adjusted Closing Price\")+ theme_minimal()\nihe_plot\n\n\n\n\n\n\n\nCode\nihe.ts = subset(ihe_df, select = Adj.Close)\n\nihe.ts = ts(ihe.ts, start=c(2019,1),frequency = 365.25) #per day for stock market price\n\nautoplot(ihe.ts, main = \"U.S. Pharmaceuticals IHE Stock Price (2019-2022)\", xlab = \"Date\", ylab = \"Adjusted Closing Price\")\n\n\n\n\n\nYou may consider employing the decomposition method to unveil the seasonality present within your dataset. To enhance the quality of your analysis, you might also explore differencing or detrending techniques to achieve stationarity in the data."
  },
  {
    "objectID": "Data_Exploration.html#identifying-outliers",
    "href": "Data_Exploration.html#identifying-outliers",
    "title": "Data Exploration",
    "section": "Identifying Outliers",
    "text": "Identifying Outliers\nExamining the decomposition plot enables us to identify any outliers present in the dataset. However, as illustrated by the plot below, there are no outliers detected in this particular dataset.\n\n\nCode\nadditive_ihe = ts(ihe.ts, frequency = 12)\ndecompose_ihe = decompose(additive_ihe, \"additive\")\nautoplot(decompose_ihe)\n\n\n\n\n\nUpon observation, it is evident that there are rising trends and potential seasonality present in the data. Moving forward, our next step is to examine the lag plot to assess autocorrelation, as well as the ACF (Autocorrelation Function) and PACF (Partial Autocorrelation Function) plots to aid in model selection. Utilizing the ACF and PACF plots will not only assist us in identifying the appropriate model for subsequent analysis but will also serve to verify the stationarity of the data."
  },
  {
    "objectID": "Data_Exploration.html#correlation-analysis",
    "href": "Data_Exploration.html#correlation-analysis",
    "title": "Data Exploration",
    "section": "Correlation Analysis",
    "text": "Correlation Analysis\nInvestigate the relationships among variables with the use of gglagplot() function to assess autocorrelation in the context of stock market data. The results obtained indicate a unanimous positive correlation across all considered variables.\n\n\nCode\ngglagplot(ihe.ts, do.lines = FALSE) + xlab(\"Lags\") + ylab(\"Yi\") + ggtitle(\"Lag Plot: IHE ETF Adjust Closing Prices\") + theme(axis.text.x = element_text(angle=45, hjust = 1))"
  },
  {
    "objectID": "Data_Exploration.html#acf-and-pacf",
    "href": "Data_Exploration.html#acf-and-pacf",
    "title": "Data Exploration",
    "section": "ACF and PACF",
    "text": "ACF and PACF\n\n\nCode\nggAcf(ihe.ts, 48, main=\"ACF for IHE Stock Market\")\nggPacf(ihe.ts, 48, main=\"PACF for IHE Stock Market\")\n\n\nWarning message in ggplot2::geom_segment(lineend = \"butt\", ...):\n“Ignoring unknown parameters: `main`”\nWarning message in ggplot2::geom_segment(lineend = \"butt\", ...):\n“Ignoring unknown parameters: `main`”\n\n\n\n\n\n\n\n\nThe dataset evidently lacks stationarity, a claim substantiated by the Augmented Dickey-Fuller (ADF) test results, affirming the necessity to proceed with differencing the dataset for further analysis."
  },
  {
    "objectID": "Data_Exploration.html#hypothesis-generation",
    "href": "Data_Exploration.html#hypothesis-generation",
    "title": "Data Exploration",
    "section": "Hypothesis Generation",
    "text": "Hypothesis Generation\nHypothesis Test:\n\\(H_o\\): Data has unit roots; hence the series is not stationary\n\\(H_a\\): Data does not have unit roots; hence the series is stationary\nDecision: If p-value is smaller than \\(\\alpha=0.05\\) significance level, we reject \\(H_o\\). If p=value is greater than \\(\\alpha=0.05\\) significance level, then we do not reject \\(H_o\\).\n\n\nCode\ntseries::adf.test(ihe.ts)\n\n\n\n    Augmented Dickey-Fuller Test\n\ndata:  ihe.ts\nDickey-Fuller = -2.7192, Lag order = 10, p-value = 0.2739\nalternative hypothesis: stationary\n\n\nConclusion: Since p-value from ADF test is 0.2739, we have not enough evidence to reject the null hypothesis \\(\\alpha=0.05\\) significance level. Thus, the time series is not stationary. We can differencing the dataset to fix this issue."
  },
  {
    "objectID": "Data_Exploration.html#acf-and-pacf-1",
    "href": "Data_Exploration.html#acf-and-pacf-1",
    "title": "Data Exploration",
    "section": "ACF and PACF",
    "text": "ACF and PACF\nACF (AutoCorrelation Function) and PACF (Partial AutoCorrelation Function) plots, when applied to data that has undergone first-order differencing, serve as valuable tools in ascertaining the stationarity of the dataset.\n\n\nCode\na &lt;- ihe.ts %&gt;% diff(difference=1, lag=1) \nggAcf(a, 10)\n\nb &lt;- ihe.ts %&gt;% diff(difference=1, lag=1) \nggPacf(b, 10)\n\n\n\n\n\n\n\n\nThe ACF plot exhibits the strongest correlation at lags 1 and 2, suggesting that q should be set to either 1 or 2. Similarly, the PACF plot demonstrates optimal correlation at lags 1 and 2, indicating that p could be 1 or 2. Given that we have applied first differencing just once, we have d set to 1.\nNow, our objective is to identify the most suitable model based on criteria such as AIC, BIC, and AICc, and subsequently, we will compare these results with the insights obtained from the ACF and PACF plots.\n\n\nCode\nihe.diff = diff(ihe.ts)\n\n\n\n\nCode\nd=1\ni=1\ntemp= data.frame()\nls=matrix(rep(NA,6*12),nrow=12) # roughly nrow = 4x3x1\n\n#d is already defined and no need to run for loop\nfor (p in c(1,2)) {\n  for(q in c(1,2))\n    {\n        \n        if(p+d+q-1&lt;=8) #usual threshold\n        {\n        \n        model&lt;- Arima(ihe.ts,order=c(p-1,d,q-1),include.drift=TRUE) \n        ls[i,]= c(p-1,d,q-1,model$aic,model$bic,model$aicc)\n        i=i+1\n        #print(i)\n        \n      }\n    }\n}\n\ntemp= as.data.frame(ls)\nnames(temp)= c(\"p\",\"d\",\"q\",\"AIC\",\"BIC\",\"AICc\")\n\n#temp\nknitr::kable(temp)\n\ntemp[which.min(temp$AIC),]\ntemp[which.min(temp$BIC),]\ntemp[which.min(temp$AICc),]\n\n\n\n\n|  p|  d|  q|      AIC|      BIC|     AICc|\n|--:|--:|--:|--------:|--------:|--------:|\n|  0|  1|  0| 4154.424| 4164.249| 4154.436|\n|  0|  1|  1| 4145.940| 4160.678| 4145.964|\n|  1|  1|  0| 4144.380| 4159.118| 4144.404|\n|  1|  1|  1| 4143.490| 4163.141| 4143.530|\n| NA| NA| NA|       NA|       NA|       NA|\n| NA| NA| NA|       NA|       NA|       NA|\n| NA| NA| NA|       NA|       NA|       NA|\n| NA| NA| NA|       NA|       NA|       NA|\n| NA| NA| NA|       NA|       NA|       NA|\n| NA| NA| NA|       NA|       NA|       NA|\n| NA| NA| NA|       NA|       NA|       NA|\n| NA| NA| NA|       NA|       NA|       NA|\n\n\n\nA data.frame: 1 × 6\n\n\n\np\nd\nq\nAIC\nBIC\nAICc\n\n\n\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n\n\n\n\n4\n1\n1\n1\n4143.49\n4163.141\n4143.53\n\n\n\n\n\n\nA data.frame: 1 × 6\n\n\n\np\nd\nq\nAIC\nBIC\nAICc\n\n\n\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n\n\n\n\n3\n1\n1\n0\n4144.38\n4159.118\n4144.404\n\n\n\n\n\n\nA data.frame: 1 × 6\n\n\n\np\nd\nq\nAIC\nBIC\nAICc\n\n\n\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n&lt;dbl&gt;\n\n\n\n\n4\n1\n1\n1\n4143.49\n4163.141\n4143.53\n\n\n\n\n\nThe AIC and adjusted AIC favor the ARIMA(1,1,1) model, while the BIC indicates that ARIMA(1,1,0) is the preferable option for model selection. To discern the most suitable ARIMA model, we should conduct a thorough examination of the diagnostic metrics associated with each model.\n\n\nCode\nset.seed(123)\n\nihe.arima111 = capture.output(sarima(ihe.diff, 1,1,1))\n\nihe.arima110 = capture.output(sarima(ihe.diff, 1,1,0))\n\n\n\n\n\n\n\n\nThe ARIMA(1,1,1) model has proven to be more effective, prompting us to select it for our analysis. With this model in place, we are now well-equipped to proceed with forecasting.\n\n\nCode\ncat(ihe.arima111[45:65], ihe.arima111[length(ihe.arima111)], sep = \"\\n\")\n\n\n\nsigma^2 estimated as 3.596:  log likelihood = -2070.62,  aic = 4149.25\n\n$degrees_of_freedom\n[1] 1001\n\n$ttable\n         Estimate     SE   t.value p.value\nar1       -0.1094 0.0314   -3.4838  0.0005\nma1       -1.0000 0.0028 -362.9830  0.0000\nconstant  -0.0002 0.0002   -1.0385  0.2993\n\n$AIC\n[1] 4.132718\n\n$AICc\n[1] 4.132741\n\n$BIC\n[1] 4.152286"
  },
  {
    "objectID": "recordNB.html",
    "href": "recordNB.html",
    "title": "Feature Selection for Record Data",
    "section": "",
    "text": "The foremost aim of the Feature Selection module within this project is to meticulously pinpoint and select the most pertinent and insightful features (variables or attributes) present in the dataset, tailored specifically for the task at hand. By doing so, we can significantly elevate the performance of the model, mitigate overfitting, and bolster the clarity and comprehensibility of the outcomes. In this section, we are focusing on labeled record data. Results of this section suggest the best model to use for analysis and forecast the future performance using train and test models.\nCode\nlibrary(tidyverse)\nlibrary(tidyquant)\nlibrary(ggplot2)\nlibrary(forecast)\nlibrary(astsa) \nlibrary(xts)\nlibrary(tseries)\nlibrary(lubridate)\nlibrary(plotly)\nlibrary(dplyr)\n\n#load df\nihe_df &lt;- read.csv(\"cleaned_data/IHE.csv\")\n\nihe_df$Date = as.Date(ihe_df$Date)"
  },
  {
    "objectID": "recordNB.html#train-and-test-model",
    "href": "recordNB.html#train-and-test-model",
    "title": "Feature Selection for Record Data",
    "section": "Train and Test Model",
    "text": "Train and Test Model\nInitially, we will partition the dataset into training and testing subsets. Following that, we will proceed to train the model using the auto.arima() function, setting the stage for us to execute the prediction function subsequently. Train model will be use in test model by calculation benchmark methods and errors to compare.\n\n\nCode\nihe.ts = subset(ihe_df, select = Adj.Close)\n\nihe.ts = ts(ihe.ts, start=c(2019,1),frequency = 365.25) #per day for stock market price\n\nihe.diff = diff(ihe.ts)\n\ntrain &lt;- ts(ihe.diff[1:799])\ntest &lt;- ts(ihe.diff[800:1005])\n\nfit = auto.arima(train, seasonal = FALSE)"
  },
  {
    "objectID": "recordNB.html#forecast",
    "href": "recordNB.html#forecast",
    "title": "Feature Selection for Record Data",
    "section": "Forecast",
    "text": "Forecast\nWe have constructed two distinct ARIMA models, utilizing the values of p, q, and d derived from prior analyses. This approach enables us to forecast future stock market values by comparing the performance of the two models, ultimately allowing us to ascertain which model delivers the most accurate predictions.\n\n\nCode\narimaModel_1 &lt;- arima(ihe.diff, order = c(1,1,1))\narimaModel_2 &lt;- arima(ihe.diff, order = c(1,1,0))\n\nforecast1=predict(arimaModel_1, length(test))\nforecast2=predict(arimaModel_2, length(test))\n\n#ts to df\nts_df &lt;- data.frame(date = time(ihe.diff), value = as.numeric(ihe.diff))\ntrain_df &lt;- data.frame(date = time(ihe.diff)[1:799], value = as.numeric(ihe.diff)[1:799])\nforecast1_df &lt;- data.frame(date = time(ihe.diff)[800:1005], value = forecast1$pred)\nforecast2_df &lt;- data.frame(date = time(ihe.diff)[800:1005], value = forecast2$pred)\n\n#plot forecast\nggplotly(ggplot() +\n    geom_line(data = train_df[1:799,], aes(x = date, y = value, \n              color = \"Train Values\"), linetype = \"solid\", alpha=0.6, show.legend = TRUE) +\n    geom_line(data = forecast1_df, aes(x = date, y = value, color = \"ARIMA(1,1,1)\"), \n              linetype = \"solid\", show.legend = TRUE) +\n    geom_line(data = forecast2_df, aes(x = date, y = value, color = \"ARIMA(1,1,0)\"), \n              linetype = \"solid\", show.legend = TRUE) +\n    labs(x = \"Date\", y = \"IHE Stock Price\", title = \"Forecasting ARIMA(1,1,1) and ARIMA(1,1,0)\") + theme_minimal() +\n    scale_color_manual(name = \"Forecast\", \n                       values = c(\"ARIMA(1,1,1) Forecast\" = \"lightblue\",\"ARIMA(1,1,0) Forecast\" = \"lightpink\"),\n                       labels = c(\"ARIMA(1,1,1) Forecast\", \"ARIMA(1,1,0) Forecast\")))\n\n\n\n\n    \n        \n        \n\n\n\n\n\n\n\n    \n    \n        \n\n    \n\n\n\nAs you can observe, the ARIMA(1,1,1) model outperforms the ARIMA(1,1,0) model. Consequently, our attention will now shift to concentrating on the ARIMA(1,1,1) model. We will proceed to run predictions using a more advanced visualization tool, incorporating both differenced data and drift to enhance the accuracy and interpretability of our results.\n\n\nCode\nihe.diff %&gt;% Arima(order = c(1,1,1), include.drift = TRUE) %&gt;% forecast %&gt;% autoplot()+ ylab(\"IHE Stock Market Prediction\")+theme_minimal()\n\n\n\n\n\nThe prediction plot provides a visual representation of the confidence intervals and potential future scenarios for stock market prices.\nWe can now narrow our focus to a smaller prediction window in order to observe the differences and assess how the prediction forecast performs in comparison to benchmark methods."
  },
  {
    "objectID": "recordNB.html#windor-for-forecast-2020-2021",
    "href": "recordNB.html#windor-for-forecast-2020-2021",
    "title": "Feature Selection for Record Data",
    "section": "Windor for Forecast (2020-2021)",
    "text": "Windor for Forecast (2020-2021)\n\n\nCode\nihe.diff2 = window(ihe.diff, start=2020, end=2021)\nautoplot(ihe.diff2)+ggtitle(\"IHE Stock Market Cost 2020-2021 (1st-order differenced)\")+xlab(\"Year\")+ylab(\"IHE Stock Market Cost (Differenced)\")+theme_minimal()\n\n\n\n\n\nThe selection of the time window between 2020 and 2021 is deliberate, owing to the outbreak of COVID-19 in 2020, which exerted a profound influence on the entire community. This pandemic has precipitated significant shifts, altering everything from previous stock prices and fundamentally transforming our societal landscape."
  },
  {
    "objectID": "recordNB.html#benchmark-methods---metrics",
    "href": "recordNB.html#benchmark-methods---metrics",
    "title": "Feature Selection for Record Data",
    "section": "Benchmark Methods - Metrics",
    "text": "Benchmark Methods - Metrics\nHere, we can employ both the mean and the naive methods as baseline forecasting approaches, providing a comparative analysis alongside the more sophisticated ARIMA model. This comparison allows us to better assess the performance and suitability of each method in predicting future data points.\n\n\nCode\nihe.mean = meanf(ihe.diff2, h=10)\ncheckresiduals(ihe.mean)\n\n\n\n    Ljung-Box test\n\ndata:  Residuals from Mean\nQ* = 66.997, df = 73, p-value = 0.6756\n\nModel df: 0.   Total lags used: 73\n\n\n\n\n\n\n\n\nCode\nihe.naive = naive(ihe.diff2, h=10)\ncheckresiduals(ihe.naive)\n\n\n\n    Ljung-Box test\n\ndata:  Residuals from Naive method\nQ* = 191.2, df = 73, p-value = 1.564e-12\n\nModel df: 0.   Total lags used: 73\n\n\n\n\n\n\n\n\nCode\nihe.diff2=window(ihe.diff, start=2019, end=2022)\nautoplot(ihe.diff) + autolayer(meanf(ihe.diff, h=10), series = \"Mean\", PI=FALSE)+ autolayer(naive(ihe.diff, h=3), series = \"Naive\", PI=FALSE)+\n  ihe.diff %&gt;% Arima(order = c(1,1,1), include.drift = TRUE) %&gt;% forecast %&gt;% autolayer(series = \"ARIMA(1,1,1)\", PI=FALSE)+\n  ggtitle(\"Forecasting IHE Stock Market Price\")+xlab(\"Year\")+ylab(\"Stock Price (Differenced)\")+guides(colour=guide_legend(title = \"3 Yr Forecast\"))+theme_minimal()\n\n\nWarning message in window.default(x, ...):\n“'start' value not changed”\nWarning message in window.default(x, ...):\n“'end' value not changed”\n\n\n\n\n\nThe displayed plot illustrates forecasts extending three years into the future, utilizing ARIMA, mean, and naive methods for prediction. Evidently, the ARIMA model significantly outperforms the mean and naive methods, showcasing a higher level of accuracy and reliability in its predictions. Given these observations, it is reasonable to deduce from the forecast plot that the ARIMA model stands out as the superior choice, prompting us to proceed with it as the preferred model for our forecasting endeavors.\nThis assertion can be substantiated by delving into tables of benchmark methods, where a comparative analysis of accuracy between the training and testing models can be conducted, alongside computations of Mean Error (ME), Root Mean Square Error (RMSE), Mean Absolute Error (MAE), Mean Absolute Percentage Error (MAPE), Mean Absolute Scaled Error (MASE), and AutoCorrelation Function at lag 1 (ACF1). In this segment, while the accuracy is being calculated automatically, we will also engage in a comprehensive discussion on the various evaluation metrics employed to gauge the Naive Bayes classifier’s performance, including accuracy, precision, recall, and the F1-score, ensuring a thorough understanding and robust assessment of the model’s capabilities.\n\n\nCode\npred &lt;- forecast(fit, 326) #annual\naccuracy(pred)\nf1 &lt;- meanf(train, h = 326)\naccuracy(f1)\nf2 &lt;- naive(train, h = 326)\naccuracy(f2)\nf3 &lt;- rwf(train, drift = TRUE, h = 326)\naccuracy(f3)\n\n#calculate by using undergrad notes\nmae1 &lt;- abs(mean(as.numeric(pred$mean) - as.numeric((test))))\nmae11 &lt;- abs(mean(as.numeric(f1$mean) - as.numeric((test))))\nmae12 &lt;- abs(mean((as.numeric(f2$mean) - as.numeric((test)))))\nmae13 &lt;- abs(mean((as.numeric(f3$mean) - as.numeric((test)))))\n\nmse1 &lt;- abs(mean((as.numeric(pred$mean) - as.numeric((test)))^2))\nmse11 &lt;- abs(mean((as.numeric(f1$mean) - as.numeric((test)))^2))\nmse12 &lt;- abs(mean((as.numeric(f2$mean) - as.numeric((test)))^2))\nmse13 &lt;- abs(mean((as.numeric(f3$mean) - as.numeric((test)))^2))\n\ndf &lt;- data.frame(\n  Model = c(\"Arima\", \"Mean Forecast\", \"Naive\", \"Random Walk Forecast\"),\n  MAE = c(mae1, mae11, mae12, mae13),\n  MSE = c(mse1, mse11, mse12, mse13)\n) %&gt;% mutate_if(is.numeric, round, 3)\nprint(df)\n\n\n\nA matrix: 1 × 7 of type dbl\n\n\n\nME\nRMSE\nMAE\nMPE\nMAPE\nMASE\nACF1\n\n\n\n\nTraining set\n0.1068385\n1.927508\n1.443424\nInf\nInf\n0.6684412\n0.02125072\n\n\n\n\n\n\nA matrix: 1 × 7 of type dbl\n\n\n\nME\nRMSE\nMAE\nMPE\nMAPE\nMASE\nACF1\n\n\n\n\nTraining set\n1.974266e-17\n1.990964\n1.463855\n-Inf\nInf\n0.6779027\n-0.1309626\n\n\n\n\n\n\nA matrix: 1 × 7 of type dbl\n\n\n\nME\nRMSE\nMAE\nMPE\nMAPE\nMASE\nACF1\n\n\n\n\nTraining set\n-0.00222457\n2.995515\n2.159388\n-Inf\nInf\n1\n-0.6000132\n\n\n\n\n\n\nA matrix: 1 × 7 of type dbl\n\n\n\nME\nRMSE\nMAE\nMPE\nMAPE\nMASE\nACF1\n\n\n\n\nTraining set\n6.904112e-17\n2.995514\n2.159349\n-Inf\nInf\n0.9999819\n-0.6000132\n\n\n\n\n\nWarning message in as.numeric(pred$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\nWarning message in as.numeric(f1$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\nWarning message in as.numeric(f2$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\nWarning message in as.numeric(f3$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\nWarning message in as.numeric(pred$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\nWarning message in as.numeric(f1$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\nWarning message in as.numeric(f2$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\nWarning message in as.numeric(f3$mean) - as.numeric((test)):\n“longer object length is not a multiple of shorter object length”\n\n\n                 Model   MAE   MSE\n1                Arima 0.031 2.384\n2        Mean Forecast 0.102 2.394\n3                Naive 1.739 5.409\n4 Random Walk Forecast 2.103 6.844\n\n\nUpon scrutinizing the benchmark methods table, it becomes evident that the ARIMA model outperforms the rest, boasting the lowest Mean Absolute Error (MAE) and Mean Squared Error (MSE) values. This unequivocally positions the ARIMA model as the most suitable and accurate for this particular analysis. Conversely, the Random Walk Forecast method registers the highest MAE and MSE values, starkly highlighting its inefficacy and rendering it an unsuitable choice for reliable predictions in this context."
  },
  {
    "objectID": "recordNB.html#evaluation-metrics-for-naive-bayes-classifier",
    "href": "recordNB.html#evaluation-metrics-for-naive-bayes-classifier",
    "title": "Feature Selection for Record Data",
    "section": "Evaluation Metrics for Naive Bayes Classifier",
    "text": "Evaluation Metrics for Naive Bayes Classifier\nAs previously discussed, in benchmarking methods, we employ evaluation metrics such as accuracy to gauge the effectiveness of the Naive Bayes model and to facilitate comparisons with other models.\nAccuracy, is computed as the proportion of correctly predicted instances to the entire dataset. In R, this can be calculated using the accuracy() function. Although accuracy serves as a useful initial metric, it may not be adequately informative in scenarios involving imbalanced datasets, where the prevalence of one class substantially exceeds the other.\nPrecision, also referred to as positive predictive value, is another vital metric. It represents the fraction of true positive predictions relative to the sum of all positive predictions made. To calculate precision in R, one can use the precision() function.\nRecall, synonymous with sensitivity, denotes the proportion of true positive predictions out of all actual positive instances present in the dataset. It is indicative of the model’s proficiency in identifying positive instances. The sensitivity() function in R can be employed for this calculation.\nF-1 score, it embodies the harmonic mean of precision and recall, thus incorporating both false positives and false negatives into its calculation. Particularly useful in the context of imbalanced class distributions, the F-1 score ranges between 0 and 1, with 1 representing perfection and 0 denoting the worst possible score. In R, this score can be computed using the F_meas() function, providing a comprehensive and balanced performance evaluation."
  },
  {
    "objectID": "recordNB.html#overfitting-and-underfitting",
    "href": "recordNB.html#overfitting-and-underfitting",
    "title": "Feature Selection for Record Data",
    "section": "Overfitting and Underfitting",
    "text": "Overfitting and Underfitting\nOverfitting occurs when a model excessively attunes itself to the training data, to the extent of assimilating noise as though it were a legitimate pattern. This phenomenon not only results in a skewed understanding of the data but also compromises the model’s ability to generalize, leading to biased and inaccurate predictions when applied to new, unseen data. A practical approach to diagnosing overfitting involves contrasting the model’s performance on the training dataset with its performance on a validation or test set, providing insight into whether the model is performing optimally or if it has succumbed to overfitting.\nUnderfitting occurs when a model is overly simplistic, failing to capture the underlying complexities and patterns within the data. This condition results in biased and inaccurate outcomes, as the model lacks the necessary intricacies to make precise predictions. To alleviate underfitting, one can introduce complexity to the model, integrate additional features, or engage in feature engineering, enhancing the model’s ability to understand and interpret the data accurately.\nTo determine whether your Naive Bayes model is prone to overfitting or underfitting, a straightforward strategy involves evaluating and contrasting its performance on the training dataset against that on the validation or test dataset. If the model demonstrates stellar performance on the training data but falters significantly on the test data, it is indicative of overfitting. Conversely, consistent poor performance across both training and test datasets is a hallmark of underfitting, signaling that the model is struggling to capture the underlying patterns in the data."
  },
  {
    "objectID": "recordNB.html#conclusion",
    "href": "recordNB.html#conclusion",
    "title": "Feature Selection for Record Data",
    "section": "Conclusion",
    "text": "Conclusion\nTo effectively utilize Naive Bayes for categorizing stock trends in R, one must initiate by delineating the problem as a binary classification task, aimed at anticipating whether stock prices will rise or fall. This entails the meticulous construction of features from historical pricing, market behavior indicators, and trading volumes that the algorithm can utilize for prediction. Subsequent to the creation of binary labels reflecting price fluctuations, and ensuring the independence and numerical nature of the features, the dataset must be split into training and test groups in a manner that honors the chronological sequence of the data. Selecting a Naive Bayes model that matches the data’s distribution is critical, followed by training, thorough evaluation through metrics, and judicious application for forecasts. Considering the intricacies and unpredictable nature of financial data, it is essential to bolster the Naive Bayes predictions with further analytical insights. Despite Naive Bayes providing a solid starting point, the intricacies of financial forecasting often require more advanced models that can account for complex interdependencies not assumed by Naive Bayes."
  }
]